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This study aimed to identifY the barriers to and facilitators of adherence to antiretroviral 
therapy and attempts to understand these factors within a developing country context. A 
further aim is to add to the literature on antiretroviral adherence in South Africa. 
Questionnaires were distnbuted to 42 participants at seven sites in the Western Cape 
where it was known that people were taking antiretroviral medication. 
VI 
The study found overall that the adherence to antiretroviral therapy was facilitated by the 
knowledge of how the medication worked and the belief in the consequences of missing 
medication. However, the use of this factor within a developing country to improve 
adherence, raises other issues that need investigation. A barrier to adherence was the 
depression experienced by some of the participants in this study. A further finding that 
could indicate a trend was that black families were more involved in helping patients 
remember their medications than white families. It is suggested that more research is 












Chapter 1: Introduction 
This preliminary study is designed to investigate the factors associated with adherence 
to antiretroviral therapy (ART). Research on adherence to ART medication issues in 
South Africa, or in any developing country, takes place within contexts that differ 
from those in the developed world. This research is thus located within a socio-
political context, a context of infrastructural issues as well as stigmatization of AIDS 
(Acquired Immunity Deficiency Syndrome). Although some of these issues are 
investigated in relation to adherence, the main focus of this study is more on the 
personal issues surrounding pill taking. These contextual issues in relation to the 
delivery of treatment in a developing country such as South Africa will, however, be 
considered. 
Between 4 and 4.7 million South Africans are infected with Human 
Immunodeficiency Virus (HIV) (Garnier, 2001; Love Life, 2001). Prevention 
strategies must be an important element in South Africa's approach to the rate of 
infection whilst another part of the strategy and spectrum of care is the supply of 
ART. Research conducted both in South Africa and in other countries around the 
world has demonstrated the efficacy of ART in the form of "drug cocktails" in the 
treatment of people infected with my. ART " drug cocktails" can consist of three 
kinds of drugs, each targeting the virus at different stages of its life cycle: non-
nucleoside reverse transcriptase inhibitors (NNRTIs) and nucleoside analogues 
reverse transcriptase inhibitors (NRTIs) which both prevent the infected cells from 
converting RNA into DNA, and protease inhibitors (PIs) which prevent HIV from 
being released from infected CD4 cells (Panos Institute, 2000). Highly Active 
Antiretroviral Therapy (HAART) is a dual or triple combination oftwo antiretrovirals 
and one PI (Mistry, 2001). 
HAART has been shown to reduce the viral load to almost undetectable levels which 
means that the patients can live longer and have healthier lives (V olberding, 1999 in 
Tsasis, 2001; Orrell, Bekker & Wood, 2001). In South Africa in 2000 it was estimated 











through clinical trials and people who work for large companies who have subsidized 
medication (Simmons, 2002; Schoofs, 2002). 
Concerns expressed both internationally via the Harvard Consensus statement (2001), 
and within the South African government circles, were that people in a resource poor 
country like South Africa would find it difficult to take antiretroviral drugs 
consistently. The debate in this country has been so contentious that it has led to both 
a High Court and a Constitutional Court ruling instructing government to supply at 
least mono-therapy (one antiretroviral drug) to pregnant women. The supply, 
however, of combination therapy or HAART is going to occur in a pilot site in 
Guguletu, Cape Town (Smetherham, 2002). A further site is being planned for 
Johannesburg (personal Communication, Mcintyre, May 18,2002). Given the fact 
that at least 20000 people with mV/AIDS are taking ART this study is warranted. 
Furthermore, the plan to distribute ART via the public health system, makes studies 
like these even more imperative. 
The debate about whether resource poor countries such as countries in Africa, Asia 
and South America can deal with HAART is ongoing. mV/AIDS related costs could 
be divided into direct and indirect costs (panos Institute, 2000). Direct costs are the 
costs involved in tests for mv and other diagnostic tests, treatment and prophylaxis 
for opportunistic infections, including visits to the doctors and hospital stays and 
antiretrovirals. Indirect costs are the costs involved in physical and technical 
infrastructure (buildings and medical staff), which are shared with other aspects of 
health care. 
In the northern hemisphere antiretrovirals are funded mainly by governments or 
private companies, whereas in the southern hemisphere very few countries can afford 
to subsidise, to a greater or lesser extent, the costs of these drugs. At present, Brazil, 
Senegal, India and Thailand are supporting the costs of antiretrovirals and the 
different governments have invoked various strategies in order to deal with the costs 
of the drugs. Brazil and India have been manufacturing generic antiretrovirals by 
using a loophole in international law. Senegal, however, has set up a multi sectoral 
approach with France to deal with the distribution of antiretrovirals in that country 










Vidal et al., 2001). The South African government has consistently stated their 
concerns about the affordability of the drugs. 
3 
The issue of infrastructure within developing countries has been a concern in that the 
countries hardest hit by HIV/ AIDS, are those countries which have the lowest number 
of medical personnel, especially in the rural areas where the majority of Africans and 
Asian live (panos Institute, 2000). Other infrastructure issues include access to clean 
water, electricity, medical facilities routinely running out of basics such as painkillers, 
and poorly equipped clinics. In a developing country context it has been demonstrated 
that interruptions in antiretroviral adherence were not only due to the patients' 
inability to adhere, but was also due to financial in-affordability of the drugs and 
insufficient stock (Souteyrand, 2001). 
Another argument against the issuing of ART to people in resource poor countries in 
Africa and elsewhere is that the person on these regimens needs to understand the 
concept of taking pills at a particular time and with certain foods. USAID head, 
Andrew Natsios is reported to have said in an interview that, with the high level of 
illiteracy in Africa, he doubted whether people could tell time and therefore would not 
be able to take their medication on time. This statement has been agreed to by some, 
most notably South Africa's minister of health, and been deemed racist by others, 
such as Frommer (2001). 
Despite all the skepticism regarding whether or not resource poor countries can deal 
with HAART, some success stories have emerged in some countries such as Brazil 
with its dedicated HIV / AIDS clinics and high adherence rates, Senegal, Botswana, the 
HAART- DOTS (directly observed therapy) programme in Haiti and the success ofa 
trial done in Cape Town. These reports have demonstrated that people in African and 
other developing countries people can adhere as much, or better than, people in the 
developed world (Farmer, 2001; Mbewu, 2001; Medrum, 2001; Orrell et al., 2001; 
Pablos- Mendez, 2001). The question therefore whether adequate adherence can be 
attained in a developing context has been answered. Although rates of adherence have 
been researched and reported on, virtually no published articles exist about what 
factors, besides those mentioned already, promote or impede adherence. But, 











stated in the DHHS guidelines cited as an authority by the CDC in Atlanta: "imperfect 
adherence is common in the United states" (Frommer, 2001). Also contrary to 
Natsios' views that African patients will have particular problems is the statement that 
within America clinicians are reminded that factors such as "gender, race, socio-
economic status, educational level, and past history of drug use" do not reliably 
predict poor adherence." Conversely, according to Frommer (2001), as reported in an 
article in JAMA 1998, a high educational level and high socio- economic status does 
not predict adequate adherence. 
Stigma is a major obstacle in most developing countries. A study from Brazil reported 
that although "the type of therapeutic may have had some bearing on patient 
adherence, life style adaptation and problems related to stigma of the disease were 
actually more important" (Melchior, Nemes, Jordan, Okasaki & Komatsu, 2000). 
Stigma is also an issue that has also been raised in relation to access to treatment in 
Africa and elsewhere. It was reported by Ezama (2001) that in Uganda many people 
including the wealthy and weB-educated sectors of the population presented with late 
stage mv disease. The time of the presentation according to Ezama (2001) was 
related to the effects of stigma. In South Africa, Govender, McIntyre, Grimwood & 
Maartens (2000) reported that people travel away from their homes and attend clinics 
elsewhere because of perceived stigma attached to mv. Mann (1990) pointed out that 
health care workers (HCW's) responses followed a pattern of initially not wanting to 
work in the mY/AIDS field because of the stigma attached to AIDS. Although no 
direct studies have been done in South Africa on the care delivered to mY/AIDS 
patients, what has been noted in other countries is that doctors and nurses could 
perceive these patients as being less deserving of care (McCann, 1999). Lengner 
(2002) stated that, in the sample of nurses interviewed at a psychiatric hospital in 
South Africa, many participants exhibited strong feelings of "revulsion" towards 
mv I AIDS patients. 
In essence, the context within which this study occurs, is that the South African 
government does not appear to support the mass distribution of antiretrovirals, 
because of the costs involved, both direct and indirect, the perception that the high 
levels of illiteracy will interfere with people's ability to adhere to the regimens and 










concerns need to be balanced by evidence from the developing world as well as the 
one published study in South Africa (Orrel et aI., 2001) that people can maintain a 
high adherence rate and the acknowledgement that in South Africa increasing 
numbers of people are taking ART. 
Pilot studies of patients' perceived barriers and facilitators to ART are needed, 
because although adherence rates had been studied in the Orrell et aL (2001) study, 
that study was not designed to look at barriers and facilitators and the only barrier 
noted was the complexity of the regimen the patients were on. 
5 
The structure of this thesis is as follows: Chapter 2 is a review of the literature 
organized around patient related, regimen related, clinician related and disease related 
factors. The international literature is summarized and literature relating to 
tuberculosis medication is considered with a view to identifying barriers and 
facilitators to adherence. The single reported study on adherence in Cape Town is 
discussed. A rationale for the present study is considered. In Chapter 3 the 
quantitative methodology is discussed, the research tool and the changes made is 
discussed as well as a motivation for the use of self-report in adherence studies. In this 
chapter the data handling and statistical analysis as well as possible limitations are 
discussed. Chapter 4 provides the descriptive statistics as well as the results from the 
correlations and regression analysis. In Chapter 5 the findings are discussed and 
placed within a South African context. Limitations of this study are offered and 











Chapter 2: Literature Review 
A review of the recent literature on AIDS and related issues was conducted by 
searching the electronic journals section of the Internet using the words AIDS, 
antiretrovirals and adherence, and by scanning the relevant journals. A major source 
of information was the review article by Tsasis (2001). By cross-referencing the 
bibliographies of the different articles, seminal articles started to emerge. These 
articles were gathered as far as possible via the Internet as well as ordering them via 
the library. Library searches and collection of articles occurred between February 
2002 and May 2002. Other sources from which articles were gathered were the 
abstract CDs from the Durban 2000 International AIDS conference. These articles and 
poster session presentations were requested via e-mail. The major bodies of work 
investigated in relation to adherence were mainly drawn from developed countries 
such as the USA, UK and countries on the European continent. It should be noted that 
thus far only one article (Orrell et aI., 2001) on adherence to antiretroviral medication 
has been published in an academic journal in South Mrica. 
It is important to point out that although the literature refers to adherence and 
compliance, compliance according to Williams (2001) suggests "obedience to health 
care professionals", whereas adherence suggests a more collaborative effort between 
the health care professional and patient in ensuring success in taking medication. For 
this reason the term adherence is used in this study. Adherence as reviewed in this 
section concerns the factors associated with adherence and non-adherence to pill 
taking regimes. A lesser amount ofliterature is about adherence to other medical 
recommendations such as medical appointments, nutritional or pharmacological 
counseling, other rehabilitation programs such as alcohol or drug counseling or other 
service utilization such as physiotherapy etc., which may all be part ofthe spectrum of 
care offered to HIV positive individuals. 
Adherence to medications has long been a focus of study (Rabkin & Chesney, 1998). 
It has been estimated that non-adherence to prescribed medications in the general 
population ranges from 10 to 92% with an average incidence of 50% (Eraker et aI., 











medications has shown that such medication is difficult to take and only about 50% of 
people do take them (Eraker et aI., 1984 in Singh & Squier, 1996). According to the 
Hopkins Report adherence follows a J shaped curve with 50% of patients taking 
medication over 80% of the time, 20% taking medication 50-80% of the time, and 
30% taking medication less than 50% of the time (Eldred & Cheever, 1998). 
Similar figures of20- 80% non-adherence to medications other than antiretrovirals 
was quoted by Williams (2001). It has also been estimated that the incidence of non-
adherence among patients with chronic illnesses is even higher (Haynes, 1979 in 
Singh & Squier, 1996). An important difference between other chronic medications, 
such as hypertension and diabetes medication, and antiretrovirals is that if patients on 
the aforementioned regimens only take half their medication and then improve their 
adherence, they will still receive the full benefit of the medication (Williams, 2001). 
However, with antiretroviral medication, besides the lack of reinforcement, such as 
immediate tangible benefits, the future effectiveness of this medication and even of 
those in a related class of antiretroviral medication will be compromised if adherence 
is not maintained (Bamberger et al., 2000b; Catz, Kelly, Bogart, Benotsch & 
McAuliffe, 2000; Williams, 2001). Therefore, studying the adherence rates and 
reasons for adherence and non- adherence of persons taking combination 
antiretroviral therapy becomes important, as 95% adherence has a significant impact 
on the virus (paterson, 1999 in Ostrop & Gill, 2000; Tuldra et at, 2000). In the Tuldra 
et at (2000) study it was noted that adherence was high for the first few months but 
declined over one year. A further impetus for studying the factors affecting adherence 
and non-adherence is the fact that non-adherence has both dire consequences for the 
individual, such as the development of resistant strains of the virus, and the possibility 
that these could be passed to others in the community during high risk activities. This 
transmission of these multi-drug resistant strains could potentially pose a public 
health risk (Bamberger et al., 2000b; Hecht et al., 1998 in Catz et al., 2000; Wainberg 
& Friedland, 1998). 
Adherence to ART has thus become an important focus of study and has been studied 
extensively searching for variables or factors that are correlated to adherence. 
Although these factors have been sought by a number of researchers it has to be 










prescribed medications (Kennedy, 2000), but is also about changes in nutritional 
health status and having to change diets, keeping medical appointments to check 
efficacy of drug regimens, other medical conditions that may arise or medical 
conditions that the person has had before and mental health status such as depression 




Adherence is not just about taking a pill but is a multidimensional process. This 
process includes a patient and hisl her specific characteristics such as the past history 
of adherence, social support, history of substance use, knowledge of the disease, or 
pre-existing illnesses. Adherence would depend on the type of treatment received, 
which includes such specific characteristics of the medication such as the type of 
medications, the duration the person would need to take it, frequency, complexity of 
the regimens, inconvenience, efficacy of medication and side effects. Environmental 
factors would impact on this process with specific characteristics such as scheduling, 
confidentiality, a comprehensive program that could include home visits or follow-up 
such as telephone calls and the location or incentive offered such as enablers, for 
example, food parcels or money. Another factor is that the disease (HIV/AIDS) has 
characteristics such as chronicity, symptomatic status, cultural norms attached to it, as 
well as education or health status. The providers of health care also have an impact 
and it depends on whether they are specialized, what level ofIDV/AIDS training they 
are exposed to, sensitivity or personal beliefs about IDV I AIDS, as well as patient-
provider factors such as the relationship and communication that exists between them 
and what type of reinforcement is supplied for adherence (Kennedy, 2000). A way of 
organizing the factors or variables that affect adherence is one offered by Tsasis 
(2001) in four broad areas or categories, namely "patient related", "regimen related", 
"clinician related" and "disease related" factors. The rest of the review will use these 
categories or factors as an organizing principle to explore the impact these factors 
have on adherence. Although this organization is used it should be noted that the 










2.1. Patient related factors 
2.1.1. Demographics: 
9 
Demographic factors have been used in the search for predictors of adherence. The 
most common factors that have been investigated include age, levels of education, 
race, sex, socio-economic status and occupation. Overall adherence does not seem to 
be predicted by gender, race, education level or occupation (Frommer, 2001; Griffith, 
1990, Lopez-Saurez, 1998 in Tsasis, 2001). Support for the contention that 
demographics are not good predictors of adherence was offered by Pratt et al. (2001) 
in their study in which age, social class, ethnicity and level of education were not 
associated with adherence. Another study found that variables such as marital status 
and personality factors also did not consistently predict adherence (Meichenbaum & 
Turk in Rabkin & Chesney, 1998). Specific demographic factors are discussed below. 
a. Age: 
Although some studies have shown that a younger age may predict poorer adherence, 
in other studies no such an association has been shown (pratt et aI., 2001; Holzemer, 
1999, Roca, 2000 in Williams, 2001). Gordillo, del Arno, Soriano & Gonzalec- Lahoc 
(1999) in a study in Spain found that younger people tended to have poorer adherence 
rates than older individuals. A possible explanation for this difference in findings was 
that in the Gordillo et aI. study almost 44% of the study population were intravenous 
drug users (IVDU). Their findings may have been influenced in that the younger 
population in their study may have had a larger proportion of drug users. However, it 
was found that adolescents did present with some difficulties with regards to 
adherence and only 41% reported adherence (Murphy, Durako, Muenz & Belzer, 
2001; Rogers, Miller, Murphy, Tanney & Fortune, 2001). But as was pointed out in 
the Rogers et al. study, anecdotal evidence pointed to the fact that adolescents' pill 
taking behaviour was affected by the presence of friends. Thus although a younger 
c--
age might be a factor, it was influenced by other factors such as possible greater drug 
usage and the developmental stage adolescents are in. Therefore although overall it 
would seem that that younger people may have greater difficulties, with adherence it 
might be contingent on other factors. 











Adherence does not correlate with educational level (Gordillo et aI., 1999; Pratt et aI., 
2001; Williams, 2001). Kalichman, Ramachandran & Catz (1999), although finding 
that education level was not predictive of adherence, did find that literacy was 
important to long-term adherence. They further qualified this by saying that literacy 
and educational levels were not necessarily related to health literacy. Kalichman et aI. 
(1999) also stressed that health literacy, a more specific index of understanding 
medical instructions, was important to adherence. It has, however, been shown that 
people with low literacy levels use more health care resources (Kef ali des, 1999). It 
appears then that educational level was not a good predictor of whether people could 
follow a regimen or not. Low literacy could affect long-term adherence as well as 
being a drain on resources. 
c.Sex 
Most studies in the northern hemisphere have been done on men (Tsasis, 2001). This 
is partly due to the profile of the disease in America and other countries where drug 
trials have occurred (panos Institute, 2000). Some studies have shown that women 
may be at risk for non-adherence (Williams, 2001). However, others have found no 
such an association (Holzemer, 1999, Roca, 2000 in Williams, 2001). It was possible 
however, that women with dependent children adhered better than men (Tsasis, 2001). 
This review will not cover adherence among women on short courses to prevent 
mother-to-child transmission of the HI virus. No difference in adherence was noted in 
women from different races in the review performed by Johnston Roberts & Mann in 
2000. A study conducted by Johnston Roberts (2000) dealing with women and 
keeping journals over a period of a month, revealed that although the prediction of 
adherence may not be through gender, women do face obstacles such as being care-
givers to children, being too busy, subject to issues of social relationships and putting 
on weight Women also, according to this study, were worried about wasting and had 
difficulty taking the ART on an empty stomach. Another barrier was taking pills in 
public and risking exposure of their HIV status. (Johnston Roberts, 2000; Johnston 
Roberts & Mann, 2000). Taking pills in public is not only a concern for women, 
however, but also for adolescents (Murphy et aI., 2001). This is supported and 
explained by Rogers et al. (2001) reporting that since stigma to mv still persists in 
communities, taking medication regularly and consistently means that the patient may 










reprisals. A further reason for non-adherence supplied by the participants in the 
Johnston Roberts (2000) study was that if people were away from their own . 
environments they did not consider it to be "safe" to take medication. 
11 
For men, non-adherence also has some association with working outside of home and 
the connection was that patients became too busy to take their medication (Chesney et 
aI., 2000; Johnston Roberts, 2000; Johnston Roberts & Mann, 2000; Kennedy, 2000). 
Supporting evidence of this factor was gained from a study in which it was reported 
that when people, both male and female, are away from home they have to remember 
to take their medications with them (Hecht, 1998 in Chesney et aI., 2000; Johnston 
Roberts, 2000). 
Sex therefore may not be a predictor, but the actions the different sexes engage in 
during the day need to be considered, as well as the more sex associated concerns 
such as putting on weight and safety aspects of exposure of women's my status. 
d. Socio-economic factors 
Socio-economic facrors include income, household income, occupation, employment 
status and housing status. Different studies have used these as markers of the socio-
economic status of the participants of the various studies. Williams (2001) in a review 
of adherence studies states that adherence does not correlate with income. Although 
Kleeberger et al. (2001) found that socio-economic factors "significantly 
discriminated lower adherence," the lower income referred to in this study was above 
the middle income in the general population. Therefore, according to the authors, this 
difference could be attributed to other factors. In the 1999 study by Gordillo et ai., 
being employed was revealed in first level analysis as a predictive factor for 
adherence. Further analysis, however, revealed that being employed did not make 
much difference. Socio-economic problems such as homelessness, substance abuse 
and alcoholism were listed as factors affecting adherence (Smith, 1996, O'Brien, 
1996, Weidle, 1998 in Tsasis, 2001). Evidence on adherence rates among the 
"marginalized, substance users and poor" have been mixed. According to Bamberger 
et al. (2000b), some studies have shown that adherence among marginalised housed, 
i.e. people living in sub-economic housing and homeless populations is not markedly 











supported this position. There are, however, practical issues that may affect adherence 
among the homeless, such as storage of medications and having food available with 
certain. medications (Bamberger et aI., 2000). 
There is still considerable debate about the use of demographic variables in the 
predictions of adherence. It does not appear, however, that demographics are a 
consistently good predictor of adherence. Although age seemed to influence 
adherence, it was contingent on other factors such as possible drug usage or 
developmental stage. Educational level was also not a good predictor although it does 
appear that health literacy may be a better predictor. Sex on its own was not a 
predictor, but looking at the different concerns such as safety aspects of taking 
medication in public and weight gain or loss may help the patient more with 
adherence. It appears that all socio-economic groups experienced difficulties with 
adherence, with the lower income group being exposed to more practical difficulties 
that have to be taken into account if adequate adherence is to occur. 
2.1.2. Mood and other psychiatric disorders 
Although psychiatric states are discussed in this section, the main focus is on 
depression, a factor that has been included in many studies thus far. It must, however, 
be remembered that when authors have referred to depression it could mean both the 
affective mood state of feeling sad and the more psychiatric definition of depression 
measured by instruments such as the Beck Depression Inventory (Rabkin & Chesney, 
1998). Depression has long been associated with immune suppression and other 
health outcomes in studies on individuals with and without chronic diseases (Ikovics 
et aI., 2001)' 
In general, research findings indicate that non-adherence seems to be associated with 
"psychological distress, emotional disturbance, depression and poor adaptive coping" 
(Singh & Squier, 1996, p 5). Rogers et al. (2001), although only from anecdotal 
evidence, speculates that the degree to which adolescents accepted their mv status 
plays a key role to initiating therapy and particularly long-term adherence. This does, 
however, demonstrate that the distress and the disturbance caused by the diagnosis 
and the resulting depression, and an inability to cope with the diagnosis, could all 











study on an adolescent cohort that higher levels of depression were significantly 
related to decreased adherence. Broers (1994) in Singh & Squier (1996) reported that 
a study conducted in Switzerland among psychiatric patients found lower rates of 
adherence although the nature of the psychiatric difficulties was not specified. Besides 
depression it was found that other psychiatric conditions such as schizophrenia and 
paranoia affected adherence (Haynes et aI., 1979, in Tsasis 2001; Kennedy, 2000). 
A study on the extent to which a psychosocial factor such as depression contributed to 
adherence with regards to AZT found that depression did affect adherence (Chesney 
et aI., 1996 in Catz et aI., 2000). Gordillo et aI. (1999) found that depressed 
individuals adhere worse than non-depressed individuals, irrespective of the social 
support they have. The design of the study did not lend itself to establish a causal link 
between depression and poor adherence (Gordillo et aI., 1999). Catz et aI. (2000) 
found that depression and severity of side effects influenced adherence. It has been 
suggested that depression with its associated features of self-neglect, lack of 
motivation and forgetfulness could affect pill-taking behaviour (Kleeberger et at., 
2001). This also might explain why, if depression is affecting the motivational 
system, the patient may be less able to cope with the side effects. 
Chesney & Folkman (1994, p164) go further by stating that besides a patient's 
previous psychiatric illnesses, the "psychological sequelae of my disease itself does 
include depression, anxiety, somatic complaints and suicide ideation" that could all 
affect adherence. In essence it would seem that both the psychiatric and more 
common understanding of depression affect adherence and should be noted in all 
patients with mY/AIDs. Also acknowledged was that psychiatric patients with other 
illnesses would pose a dilemma with regard to adherence to antiretroviral therapy. 
It appears that whereas depression affects adherence behaviour, there is no certainty 
that it also causes an accelerated mv disease progression. Some studies acknowledge 
that there might be a link (Lyketsos, 1996 in Gordillo et aI., 1999) whereas others 
have claimed there is a definite link (Zorrilla, 1996, Burack, 1993 in Gordillo et aI., 
1999) with depression used as an indicator of shorter survival period in my positive 
men (Markowitz, 1994, Mayne, 1996 in Gordillo et aI., 1999). Singh & Squier (1996) 











counts and a trend towards accelerated mortality. In the Kennedy (2000) review many 
articles cited depression as a major reason for non-adherence and patients ranked it as 
one of their most important reasons for not adhering. In a seven-year longitudinal 
study ofIllV positive women conducted by Ikovics et al. (2001), it was demonstrated 
that depressive symptoms are associated with disease progression and more negative 
outcomes. 
It appears therefore that depression not only affects adherence negatively, but also 
interferes with perceptions of social support, motivational systems, as well as having a 
negative impact on disease progression. 
2.1.3. Knowledge of and Beliefs about AIDS and Treatment 
a. Education about HIV/AIDS (disease) and adherence 
It was reported by Eldred (1997) in Tsasis (2001) that the patient's knowledge of his 
or her diagnosis, including the purpose ofthe medication regimen influenced 
adherence. Williams (2001) in her paper also commented that patients who 
understood how their medications worked to help them were more likely to adhere to 
their regimens. In another study it was found that although knowledge of the illness 
and belief in the treatment was high, it was not associated with adherence (Gordillo et 
aI., 1999). This may, however, be an anomaly due to the particular study population 
that included a high percentage ofIVDU users that may have affected the results. 
b. Self-efficacy: 
The belief and the intentions that a person holds about a particular behaviour 
influence that behaviour. However, the gap between intention and actual behaviour, in 
this case adherence to medication, needs to be explored (Sweeney et at, 1998 in 
Gordillo et ai., 1999; Strecher in Glanz, Lewis & Rimer (ed), 1997). With regard to 
adherence to medication, exposure to the side effects may influence that belief. This 
point will be discussed further under side effects (2.2.1). 
Adherence appears to be associated with a patient's belief that they can follow a 
particular medication regimen, the belief about actual or perceived side effects of the 











influenced by the beliefs about taking medication in general (Tsasis, 2001). Perceived 
self-efficacy as a variable is useful according to Tuldra et aI. (2000) in that it related 
to high levels of adherence one year after beginning ART. Self-efficacy refers to the 
ability to take the medications and patients who were non-adherent had lower self-
efficacy (Chesney et aI., 2000; Johnston Roberts, 2000; Tuldra et aI., 2000). Catz et 
aI. (2000) in their study found that perceived self-efficacy to adhere to antiretroviral 
regimens was related to adherence. Eldred (1998), in Catz et aI. (2000), noted that 
patients' beliefs about their ability to adhere even with mono-therapy (with AZT, 
zidovudine) appeared to be related to higher levels of treatment adherence. Johnston 
Roberts (2000, p. 162) found that persons who had made a decision based on an 
"active, thoughtful and informed decision" to take ART, had adhered to the regimen 
thus demonstrating their self-efficacy. 
c. Treatment Efficacy 
The belief in the treatment offered, known as treatment efficacy, in relation to 
affecting illness outcome, could be associated with adherence. (Samet, 1992, Samuels 
et aI., 1990 and Besch, 1995 in Tsasis, 2001). It was found that with mono-therapy, 
skepticism around the efficacy of AZT affected adherence (Muma et aI., 1995 in 
Singh & Squier, 1996). Besides demonstrating a lower self-efficacy, non-adherent 
patients also demonstrated a lower perceived efficacy of treatment benefits or 
medications they were using (Bamberger et aI., 2000b). Also stated in Johnston 
Roberts & Mann (2000) was that women who did not believe in the efficacy of the 
drugs had problems with adherence. In a study done with patients it was found that if 
patients believed in the efficacy of the medication, they took the medication despite 
the side effects (Johnston Roberts, 2000). Gordillo et aI., (1999) however found no 
association between belief in the treatment and adherence. 
To sum up it appears that a person's belief in self, as well as a belief in the treatment 
they are taking supports adherence despite the side effects of the medication. Chesney 
et al. (2000) suggested that training and counselling patients prior to initiating 
combination therapy could be worthwhile in fostering beliefs in treatment efficacy. It 
is also reported by Williams (2001) that using reports or graphs that demonstrate the 
medications' impact is a powerful motivating tool for continued adherence. This is 










medication on the viral load, especially if the patient was asymptomatic before 
starting treatment (further discussion under characteristics of the disease 2.4.2). 
2.1.4. Alcohol and drug usage 
16 
Non-adherence and alcohol consumption is correlated in the Chesney et aI. study 
(2000) and support for this assertion that alcohol consumption could affect adherence 
is found in Bamberger et ai., (2000b). Kennedy (2000) in his review found that non-
adherence was an issue for patients who actively used recreational drugs. The idea 
that when people take recreational drugs, they are likely to be non-adherent is 
supported by Pratt et al. (2001). However, some people who use drugs beyond the 
recreational stage, i.e. people with drug addictions, can adhere to demanding regimens 
(Bangsberg et ai., 2001 in Williams, 2001; Rabkin & Chesney, 1998). This further 
demonstrates that although factors that could impede adherence must be noted, they 
are not exclusionary. 
2.1.5. Influence of other medical conditions: 
Kennedy (2000) in a review found that ifHIV was not the only medical condition, 
this affected adherence as the person involved was taking other medication. Williams 
(2001) confirmed that very often ART medication was not the only medication 
patients were taking as they were often also on other medication regimes such as 
those for opportunistic infections. It is thus important to be aware of patients on 
multiple medications, given the possible interactions between the drugs. 
2.1.6. Common reasons for not taking ART 
One of the main patient-related characteristics for non-adherence and reasons why 
doses are skipped is that patients simply forget or sleep through doses and are busy 
with other things (Kennedy, 2000). Some patients, however, used reminders and cues, 
and according to Kemppainen, Levine, Mistal & Schmidgall (2001), this strategy was 
used more by patients over 50 years old. Patients who used the fact that medication 
interfered with their lifestyles as a reason to not adhere, were recommended to use 
planning as a means to facilitate adherence (Kemppainen et aI., 2001). It has, 
however, been noted that the extent to which the regimen interferes with the patient's 
daily life affects the adherence (Bamberger et at, 2000b; Johnston Roberts & Mann, 











by integrating it into their daily routines were more successful at adherence. This was 
particularly successful with people who had predictable daily schedules. Ostrop & 
Gill (2000) found that adherence could be improved by providing patients with 
adherence aids and devices that counteracted forgetfulness. 
2.1.7. Social Support: 
A factor that has been investigated in many studies in relation to adherence to ART 
and the high rates of adherence needed to maintain viral suppression is social support, 
which although seen and dealt with in this section as a patient factor, can also be 
viewed as an environmental factor. 
Social support has been demonstrated to buffer the impact of a wide variety of 
stressful life events including illness. Research has shown that people with illnesses 
such as malignancy, coronary artery disease and other medical conditions have with 
social support adapted better to the crises of illness, and demonstrated less anxiety, 
depression and somatic complaints (Bruhn et aI., 1984 in Swindells et aI., 1999). 
Three types of support, namely emotional, tangible and informational can be 
recognized and therefore social support can be different for different people at various 
stages of the disease. 1fit is informational and tangible support that is needed, then 
emotional support may not be satisfying, and if new symptoms arise then 
informational support may be needed (Swindells et aI., 1999). In most studies the type 
of support needed at any stage of the disease was, however, not considered and many 
studies focused only on the perceived emotional support offered by friends, families 
and by clinicians. 
A lack of social support has been shown to predict non-adherence to antiretroviral 
medication (Catz et aI., 2000; Chesney et aI., 1996; Spire et aI., 2002). Catz et aI. 
(2000) cite a study by Mostashari (1998) that showed that good emotional support 
aids adherence. Patients therefore who perceived less emotional support, and those 
who were less confident of their ability to adhere, were most likely to report 
inconsistent use ofHAART (Catz et aI., 2000). A cautionary note from Catz et aI. 
(2000) was that it was difficult to say whether this relationship was causal. Other 
researchers have found that it is important for adherence that patients have supportive 











(Johnston Roberts, 2000; Besch, 1995, Eldred, 1997 in Tsasis, 2001; Williams, 2001). 
An example where tangible support may playa role is that one of the major reasons 
for non-adherence is that no one reminded the patient to take their medication 
(Kennedy, 2000; Sarason et aI., 1988 in Murphy et aI., 2001). Patients that adhere to 
medication also report greater social and emotional support from their health care 
providers and significant others (Singh & Squier, 1994; Morse, 1991 in Tsasis, 2001). 
It was found by Kemppainen et a1. (2001, p. 125) in a study in the USA that certain 
"patients groups most influenced by positive support from health care providers, 
family and friends included non-white patients, patients under the age of 50 and 
patients with fewer years of education." This study concluded that social support was 
needed less by older people than younger people. In another study it appeared as if 
older people were less satisfied with the social support and were using more 
maladaptive coping strategies, as well as being more vulnerable to social isolation 
(Swindells et aI., 1999). In a study done in the UK, living alone was seen as a factor 
that affected non-adherence (pratt et aI., 2001). Social support according to Johnston 
Roberts (2000) meant more than just reminding patients to take their pills and also 
included cooking the correct foods and refilling prescriptions. Furthermore it was also 
stated in this study that social support could mean that the patient "modeled" the 
adherence behaviour of friends. There appears to be overall agreement that social 
support is important for adherence to ART but that it sometimes needs to be tailored 
to what the person needs at the time. 
Social support is once again not a factor that can be considered in isolation as it would 
depend for example on whether the person was open about their mv status so that 
they could access support, or whether depression was interfering with the patients 
ability to perceive and accept such support. Furthermore according to Gordillo et aI. 
(1999, p 1768), social support "does not contribute further to adherence in the 
presence of depression." Social support nevertheless appears to be an important factor 
to consider irrespective of age, with the proviso that it needs to be specific to what is 
being requested. 
2.1.8. Summary of patient related factors 
Conclusions that can be drawn from the literature thus far are that socio-demographics 











status all seem to have contingent factors that influence adherence. Depression affects 
adherence negatively and appears to impact negatively on disease progression. In 
many studies forgetfulness and sleeping through doses have been common reasons for 
not adhering. In order to adhere, it appears that people with AIDS had to have a 
knowledge of AIDS and needed to know how their treatment worked. In addition, 
people had to believe that they could adhere to the regimens they were on. A 
facilitator of adherence was if people believed in the treatment and received visual 
feedback about the effects of their treatment. Alcohol and drug usage appear to affect 
adherence negatively, but they should be seen as factors that impede adherence rather 
than be used as exclusionary factors. It also appears that if people with AIDS had 
other medical conditions and were using medication, this factor could influence their 
adherence to ART. Finally, social support appears to be an important factor for 
adherence and needs to be specifically tailored to the patient's needs. 
2.2. Regimen related factors: 
Regimen related factors include side effects, dietary requirements, complexity of 
treatment and drug holidays. 
2.2.1. Side effects 
Antiretroviral medications are extremely difficult to take and can cause a number of 
unpleasant side effects due to their toxicity (Grahame-Smith, 1998; Kemppainen et 
a!., 2001; Kennedy, 2000; Ungvarski, 1997 in Johnston Roberts & Mann, 2000; Orrell 
et al., 2001) Patients therefore need to understand the medication side effects to better 
prepare them for their onset (Kennedy, 2000). It was also found that addressing drug 
related concerns with patients was important for adherence (Tseng, 1998 in Ostrop & 
Gill, 2000). Williams (2001) goes further by stating that it was important not only to 
foster the patients' understanding of the side effects but also to teach patients how to 
manage them, and that these interventions had significant effects on adherence. It 
would appear according to Boyle (2000) that side effects are overtaking other reasons 
such as dietary restrictions and complexity of regimens for non-adherence. Patients 
are less prepared, at least in the northern hemisphere, to accept enormous discomfort, 











2.2.2. Dietary requirements 
With ART, food requirements can sometimes be complicated as some medications 
have to be taken with fatty food, some without fatty food, others on an empty 
stomach, some with water and others without water (Gallant & Block, 1998; Johnston 
Roberts, 2000). Johnston Roberts (2000) found that socio-economic issues could play 
a role here in that patients with a lower socio-economic status may not always have 
the necessary dietary resources to be able to adhere fully as some medications are 
dependent on these foods for optimal efficacy. Dietary studies in cardiovascular 
disease demonstrate that "the more regular a patient's diet the better for long-term 
compliance to a restricted diet" (Metz et al., in Gallant & Block, 1998, p. 7). Simpler 
regimens in the form of simpler dietary requirements could aid adherence (Gallant & 
Block, 1998). 
2.2.3. Complexity and dosing requirements 
The more complicated the medication regimen is, the more difficult it is for the 
patient to take it (Bailey et at, 1995 in Murphy et aI., 2001; Williams, 2001). 
Johnston Roberts (2000, p 159) also stated "the sheer magnitude of the complexity of 
the regimens was too great for patients." It was also asserted that the complexity of 
regimens affected all patients regardless of education level or age (Bailey et at, 1995 
in Murphy et aI., 2001). Kleeberger et aI. (2001) found that if the regimen contained 
more than three ART medications it was associated with lower adherence. Murphy et 
al. (2001), in his study of adolescents, reported that the number of medications that 
needed to be taken also influenced adherence. Another variable or factor that appears 
to influence the level of adherence is the frequency of dosing and not the number of 
tablets having to be taken at anyone time (Singh & Squier, 1996). This debate about 
whether the dosing requirements influence adherence was addressed by Gallant & 
Block (1998) citing a literature review by Greenberg (1984), which found that once-
daily and twice-daily dosing regimens had higher adherence than three and four times 
dosing. This is important support for the contention that adherence is affected by the 
number of daily dosing rather than the amount of tablets at each dosing. In the 
Kemppainen et al. (2001) study the simplified regimens of twice-daily dosing seemed 
to have a positive impact on adherence. In South Mrica, the Orrell et al. (2001) study 
supported this assertion. It is important that, as noted and reported by Catz et al. 











reminded that one was mv positive and experienced the psychological impact of this 
reminder. It was also reported in the Johnston Roberts & Mann, (2000, p. 6) study that 
women felt that taking pills reminded them of the chronicity of the disease as well as 
pulling them out of "normality" and into "sickness." A common reason given by 
patients for non-adherence was the confusion over regimen requirements (Catz et aI., 
2000). Regimens then, according to Friedland (1997), where possible, should be made 
as simple as possible. This simplicity is also called for because AIDS patients are 
often on other medications as well as combination therapy (Kleeberger et al., 2001; 
Williams 2001). In a study based on a once daily dose of ART it was found that the 
regimen was well accepted, tolerated and the efficacy results were comparable to 
more complicated regimens, thus confirming that adherence is affected by the 
frequency of daily dosing and not by the number of tablets at each dose (Maggiolo et 
aI., 2000). 
2.2.4. Drug Holidays 
Patients often take "drug holidays" which are defined as taking a little or no 
medication for three or more days (Johnston Roberts, 2000; Kennedy, 2000). 
Kleeberger et aL, (2001) found that this was not virologically damaging if the patient 
was otherwise perfectly adherent, but the disruption in medication did have a huge 
effect on patients who already had lowered adherence. It has according to Katzenstein 
(1997) in Kleeberger et al. (2001) been shown that reducing medications versus 
stopping drugs may result in a higher rate of resistant mutations being produced. 
Patients therefore need to negotiate drug holidays with physicians and involve 
stopping rather than reducing intake. 
2.2.5. Summary of Regimen related factors 
It appears that the regimen related factors that affect adherence to ART include the 
side- effect profiles of the medication, the complexity of the dietary requirements and 
the complexity of the daily dosing regimens. It that twice-daily dosing is more 
effective than three-times daily dosing. "Drug holidays" did not necessarily have a 
negative effect if negotiated with the physician and that it involved stopping all drugs 











2.3. Clinician Related factors 
2.3.1. Role of clinicians 
Key roles for clinicians include supplying the patients with clear explanations for the 
use of their medications, encouragement, reassurance, support and sustained follow-
up (Kennedy, 2000; Dimatteo et aI., 1993, Roberts, 2000 in Tsasis, 2001). All of these 
factors would further enhance patient adherence (Davis et al., 1997, Chung et al., 
1995 in Tsasis, 2001; Williams, 2001). It was found in Brazil that the health care skill 
at maintaining dialogue during the earliest stages of treatment was important for 
adherence (Melchior, Nemes, Jordan, Okasaki & Komatsu, 2000). 
Gordillo et al., (1999) found that they could not demonstrate a correlation between the 
relationship between patient and provider and improved adherence. The study 
concluded, however, that it was not possible to discount that this in fact may be the 
case. From a more interpersonal perspective, Friedland (1997), discussed improving 
adherence through education around mv, through involving patients in decision-
making, assisting patients, simplifying regimens and maintaining a good relationship 
with the patient. In Kennedy's (2000) study on rating predictors of adherence, this 
decision-making was last on patients' lists about things that help them adhere. In the 
Johnston Roberts (2000) study, patients reported that physicians had motivated them 
to stay on their medication. Adherence is further influenced when the physician is 
available to answer questions, has a non-judgemental attitude, reinforces the treatment 
regimen, provides positive feedback, and assists the patient to incorporate the 
treatment regimens into lifestyle (McPherson- Baker et al., 2000; Davis et al., 1997, 
Chung et al., 1995, Roberts, 2000 in Tsasis, 2001). A factor found by Capozzolo et aI. 
(2000) in Brazil was that the doctors were focusing solely on adherence to ART and 
not allowing patients any leeway to discuss their difficulties in living with the illness 
and with the treatment. With regard to interventions to improve adherence, Chesney et 
al. (1999) in Catz et aI. (2000) suggests that patient provider communication could be 
improved. 
In a study of health care providers it was pointed out that they often lacked the time, 
education and resources to prepare patients to begin combination therapy and to 











Johnston Roberts & Volberding, 1999). They often just educated people and this may 
not be effective as knowledge alone does not impact on adherence (Cummings et aI., 
1982 in Gerbert et aI., 2001; Prochaska et aI., 1992). Given time constraints that 
physicians practice under, it may often mean that an interdisciplinary approach may 
be necessary. Many studies have shown that adherence is not just about taking 
medication, but is impacted upon by many other factors. It has also been stressed in 
many papers that listening to the patient as a whole is necessary if adherence is to be 
achieved (Capozzolo et aI., 2000; Johnston Roberts, 2000; Tsasis, 2001). 
2.3.2. Clinical monitoring 
Fewer visits to physician's means less clinical monitoring and less frequent pill refills 
and lower adherence and thus may be a good marker for measurement (Kleeberger et 
aI., 2001; Lucas, Chaisson & Moore, 1999). 
2.3.3. Training of clinicians 
Another factor that could influence treatment outcome is the lack of training that 
doctors have in understanding the complexities of adhering to complicated regimens 
(Ungvarski, 1998). It has been pointed out that in South Africa the lack of 
infrastructure and training in mv medications may hamper adherence (Heywood, 
2000). Issues around training were also mentioned by Boyle (2000), who concluded 
that many clinicians have not taken full advantage of the newer, less complex 
regimens available. 
2.3.4. Summary of clinician related factors 
Clinicians need to have non-judgemental attitudes, not only towards adherence issues 
but also towards other factors that impact on patients' lives. Further training needs to 
be ongoing to keep up with the latest developments in the pharmacological field so 










2.4. Disease related factors 
The chronic condition and unique characteristics of the AIDS syndrome have both 
been investigated with regard to their effects on adherence. 
2.4.1. Chronicity of AIDS 
24 
The severity of the disease as well as its chronicity have been shown to influence 
adherence (Griffith, 1990, Gidran, 1998 in Tsasis, 2001). It has been shown with 
other chronic diseases that adherence to treatment decreases over the course of 
treatment (Hond, 1998 in Tsasis, 2001). With hypertension, half of those who begin 
treatment drop out within the first year, and of those who remain in care, only two 
thirds adhere to the correct medications (0' Brien et aL, 1996 in Tsasis, 2001). mv, 
because of its higher morbidity, has a higher adherence rate. This influence on 
adherence rates may be seen in the USA, where morbidity due to AIDS declined from 
29.4 persons per 100 to 3.7 persons per 100 after the introduction of combination 
therapy (FaBela et aL, 1998). It appears that the severity had a positive effect on 
adherence to medication for this chronic disease. 
2.4.2. Characteristics of AIDS 
. The difficulty with mv is that patients remain asymptomatic for years and this limits 
the perceived benefits from adherence to the regimen (Samet et aL, 1992 in Tsasis, 
2001). The side-effects of the medication are therefore often worse than the initial 
symptomotology. In a study by Singh & Squier (1996) it was found that having had a 
prior opportunistic infection was a positive predictor of adherence to medication and 
they concluded that asymptomatic individuals might perceive themselves as less 
vulnerable, and is thus less motivated to comply. This would be supported by the 
Health Belief model in that patients had learnt the costs and experienced the disease 
and thus would be further motivated to adhere to medications (Williams, 2001). Being 
symptomatic before treatment, according to Rogers et aL (2001), provides both 
positive and negative reinforcement when people skip doses with other chronic 
diseases. When people therefore skip doses with these diseases, each failure has 
consequences that can be learnt. With HIV, however, the long asymptomatic phase 
provides "no such incentive to initiate or adhere" (Rogers et aL, 2001~ Samet et aI., 










2.4.3. Summary of disease related factors 
Although the severity of the AIDS morbidity had a positive effect on adherence, the 
intersection with the characteristics of the disease, such as its largely asymptomatic 
initial presentation, had a negative effect on adherence. 
2.5. Conclusions drawn from the international literature 
Contrasting and sometimes contradictory results relating to most of the factors 
emerged from the various studies done in this area. No one factor can be used to 
successfully predict adherence, neither can anyone group of people be singled who 
would find it particularly difficult to adhere. 
2S 
Considerable debate still exists about the use of demographic variables in the 
predictions of adherence. It does not appear however that demographics are a 
consistently good predictor of adherence. Although age seemed to influence 
adherence it was contingent on other factors such as possible drug usage or 
developmental stage. Education level was also not a good predictor, although it does 
appear that health literacy may be a better predictor. Although sex on its own was not 
a predictor, looking at what concerned the different sexes may help the patient more 
with adherence. It appears that all socio-economic groups experienced difficulties 
with the lower income group being exposed to more practical difficulties with regard 
to adherence and these have to be taken into account if adequate adherence is to 
occur. Socio-demographics are therefore not good predictors of adherence. All socio-
demographic variables seem to have contingent factors that influenced adherence. 
Depression affects adherence negatively and seems to impact negatively on disease 
progression. In many studies forgetfulness and sleeping through doses have been 
common reasons for not adhering. In order to adhere, it appeared that people with 
AIDS had to have knowledge of AIDS and needed to know how their treatment 
worked. People on ART had to believe that they could adhere to the regimens they 
were on. A facilitator of adherence was that people believed in the treatment and 
received visual feedback about the effects of their treatment. Alcohol and drug usage 
appear to affect adherence negatively but they should be seen as factors that may 
impede adherence and were not to be used as exclusionary factors. It also appears that 
if people with AIDS had other medical conditions and were using medication, then 











Although social support is seen to be important, it is once again not a factor that can 
be considered in isolation since it would depend for example on whether the person 
was open about their mv status so that they could access support, or whether 
depression was interfering with the patients ability to perceive and accept social 
support. Social support nevertheless appears to be an important factor to consider, 
irrespective of age and needs also to be specific to what was being requested by the 
patient. 
It appears that the regimen related factors that affect adherence to ART include the 
side- effect profiles of the medication, the complexity of the dietary requirements and 
the complexity of the daily dosing regimens. It is also apparent that twice-daily dosing 
works better than three-times daily dosing. "Drug holidays" did not necessarily have a 
negative effect if negotiated with the physician and that it involved stopping all drugs 
rather than reducing intake. 
Clinicians needed to have non-judgemental attitudes, not only towards adherence 
issues, but also towards other factors that impact on patients' lives. Further training 
needed to be ongoing to keep up with the latest developments in the pharmacological 
field so that simpler regimens could be prescribed. 
Although the severity of the disease had a positive effect on adherence, the 
intersection with the characteristics of the disease such as its largely asymptomatic 
initial presentation had a negative effect on adherence. 
All these factors can interact dynamically with each other. The adherence behaviour, 
therefore, of any patient is a unique experience of the individual intersection between 
all, or part of, the factors mentioned above. When dealing with adherence behaviour it 
is important not to locate it within an individual paradigm but rather be more 
comprehensive and include the complexity and characteristics of the regimen, 
clinician behaviour, as well as social and environmental factors. 
International studies have moved beyond trying to predict, according to socio-











adherence. These studies focus on what barriers and facilitators exist for individuals 
and communities in order to enhance adherence, given the high levels of adherence 
needed to maintain virologic suppression and immunologic resurgence. This move 
was also important because the ethics involved in refusing treatment purely on the 
grounds of the patient's demographics is debatable, even given the consequences of 
poor adherence (Tchetgen, Kaplan & Friedland, 2001). Studies also have been 
conducted with patients themselves as it has been shown that physicians overestimate 
adherence as well as seeing the barriers and facilitators to adherence differently to 
patients (Kennedy, 2000). Patients therefore needed to be researched for their 
perceptions of barriers and facilitators to taking antiretrovirals. 
All the literature reports on studies performed in other countries and it is therefore 
necessary to look at the South African experience in relation to facilitators and 
barriers to adherence with other chronic medication. In South Africa the chronic 
disease tuberculosis (TB) has received attention because of the large numbers of 
people (24%) who have not completed their treatment (Assad, 2002). Adherence to 
TB medication has proved difficult in South Africa (Assad, 2002; Hansen, 2002; 
Simmons, 2002) and the factors that seem to influence adherence and have acted as 
barriers have been patient factors such as stigmatization, fear, treatment side-effects, 
time, poverty, substance use, use of traditional medicine, social mobility and external 
locus of control (Dick, 1998). Other influencing factors have been staff or clinician 
factors such as nurses being overwhelmed by numbers of patients, distancing barriers 
and neglecting the psychosocial aspects of the disease (I?ick, 1998). Another group of 
variables that may be labeled clinic factors are that nurses are task oriented, that there 
is little continuity of care, little patient education and that follow-up is sporadic. The 
factors contributing to adherence to TB medication has been that clinics are oriented 
towards acute symptoms, that the focus is on symptoms and laboratory results and 
that the patients' role in their cure is not emphasized. This all leads to poor staff-
patient relations and poor clinical outcome (Dick, 1998). 
In Cape Town it has been demonstrated that urban dwellers of all races, socio 
economic groups, language and cultural groups can adhere to ART (Orrell et ai., 
2001). It was noted in this study that the barrier to ART was the complex nature of the 












descriptors, male persons who spoke Xhosa were the poorest adherers (Orrell, Bekker 
& Wood, 2001b). However, what this study did not note was what other barriers and 
facilitators to taking medication there were. Considering what the international 
literature has stated, it could be speculated that the site used had well-qualified 
doctors with well-qualified counselors and that a supportive structure therefore was 
present at the site. Noted also in a commentary on this trial was that the languages in 
which people were cared for was mainly English and Afrikaans, and that it was 
possible that the people who did not adhere did not understand and were not educated 
about mv and the consequences of not taking medication (T AC newsletter, 2002). 
Noted also was that the site was far away from where some people stayed which may 
have been a facilitator to adherence, since it has been noted in another study that 
people traveled far distances away from their homes if they were mv positive, not 
wanting to be identified in their communities (Govender et al., 2000). However, these 
are all speculations as to what the barriers and facilitators are to taking ART in an 
urban setting. 
2.6. Rationale of the study 
Given the paucity of studies in South Africa and taking cognizance that predictors are 
not sought, a study on the barriers and facilitators to adherence to ART is needed. 
These facilitators and barriers should be sought using the organizing principles of 
patient, regimen, disease as well as social and physical environment related factors. 
This study therefore aimed to use the factors found in the international literature and 
the Adult AIDS Clinical Trials Group (AACTG) questionnaire to carry out a 
quantitative study in order to identify the major obstacles or barriers to adherence and 
to identify which factors gain significance as facilitators. These factors could include 
self- efficacy, belief in treatment, knowledge and beliefs surrounding skipping 
medications, social support issues, common reasons for not adhering, complexity of 
the drug regimen, depression, stress and alcohoVdrug usage. The study would use the 
patients' responses not to predict adherence but to possibly suggest ways of 
overcoming barriers and enhancing facilitators. Support for this kind of study is 
offered by Delaporte et al., (2001) who state that taking into account the imposition 
ART has on people's lives, such as the special diets associated with the therapy and 
the timing of doses, it therefore becomes necessary to find the factors that either 











following question: what are the factors that impede adherence and facilitate 












Chapter 3: Methodology 
3.1. Introduction 
The literature suggests that clear predictions of adherence to ART is difficult because 
of the interrelatedness of the different variables or factors. There exists few clear links 
between socio-demographic variables and adherence to ART. A greater link appears 
to exist between the presence of depression, social support and beliefs and knowledge 
about AIDS and ART and adherence. Although alcohol and drug usage impacts 
negatively on adherence they are not exclusionary factors. It appears as if side-effects 
and increasing complexity of regimens, especially if they require dosages more than 
twice-daily, have an effect on adherence. Having a well-trained and empathic doctor 
influences adherence positively and ifpatients perceive the severity of the disease, it 
also appears to impact on adherence. Although clear predictions do not seem possible, 
an option is therefore to study the factors that either facilitate or impede adherence in 
that these more often than not could be improved and thus improve adherence. 
In South Africa the one published study (Orrell et al., 2001), noted that the 
complexity of the regimen was a barrier to adherence. It is therefore necessary to 
search for factors that load positively, i.e. aid adherence, and those which load 
negatively, i.e. impede adherence in the South African context. Although it is realised 
that 95% adherence is optimal for viral suppression, the reasons for non-adherence or 
skipped doses is more important for this study which is therefore not aimed at 
measuring adherence rates, but rather concentrates on the reasons why patients miss 
or do not miss dosages. The actual kinds of medicine being taken were regarded as 
being of lesser importance. 
3.2. Study Design and Recruitment 
The study was conducted on a sample of 42 mv - infected women and men who are 
currently taking ART. These participants were recruited from seven sites in the 
Western Cape. Data was collected from July 2002 to the first week in August 2002. 
Sites that were known to have people taking HAART were telephoned and the head of 
the site was asked for permission to explain the purpose of the study and for 











so that the researcher would therefore not have direct access to the patients or clients 
and anonymity would thus be insured. No site that was approached refused access. A 
covering letter explained who the researcher was as well as the purpose of the study, 
guaranteeing not only strict confidentiality but that also the names of the sites would 
not be revealed (see appendix 1). A worker at each site would ask potential 
participants to take part in the study. Those willing to participate were handed the 
questionnaires that were self-administered. All the information divulged in the 
questionnaires was confidential and the completed questionnaires were handed back 
to the worker at the site. The participants were also promised that feedback to the sites 
would be via a report from all the participants so that the individual sites could not 
recognize which participants attended their sites. 
3.3. Measurement Instrument 
For this pilot study it was decided to use a tool designed and tested in the United 
States and which has been utilised extensively in other parts of the world (Personal 
Communication, Chesney, May 20, 2002). The questionnaire used comprised two 
parts and was designed by the Adult AIDS Clinical Trials Group (AACTG). It 
consisted ofthe baseline questionnaire (Baseline Correlates of Adherence) and the 
follow up questionnaire (Adherence to Antiretroviral Medications) (See appendix 2 
and 3 respectively). As the researcher would only have a cross sectional view it was 
decided to combine the two. 
The original questionnaires were developed by the Recruitment, Adherence and 
Retention Subcommittee of the Adult Outcomes Committee, and the Patient Care 
Committee of the AACTG. This group included social scientists, physicians, nurses 
and pharmacists. The original testing took pl~ce in 10 clinical trial sites and was self 
administered with staffbeing encouraged to assist patients when necessary. All 75 
patients were on combination therapy, including at least one PI (protease inhibitor), 
and one or more NRTI or NNRTI. The instrument was delivered between May and 
June 1997. 
Original instruments focused on recent adherence to maximize recall and minimise 
bias. Variables included were those known or hypothesized to affect adherence to 











distress and adherence self efficacy (Dunbar- Jacob, 1990, 1993, in Chesney et aI., 
2000; Ikovics and Meisler, 1997 in Chesney et aI., 2000; Wainberg and Friedland, 
1998). Some of the questions in the original questionnaires were standardized scales. 
Patients were also asked about more distal adherence, i.e. skipping medications over 
the past weekend and in the past month (Chesney et aI., 2000). Patients who reported 
skipping medications were presented with a list of 14 reasons why people were 
missing their medications and were asked to rate on a 4-point scale (never, rarely, 
sometimes, often) how often each reason applied to them (Chesney et aI., 2000). 
Other variables probed were adherence self- efficacy and beliefs about treatment 
effectiveness. A 4- point scale (,not sure at all' to 'very sure') was used. Two 
additional questions were asked: one concerned their belief in the positive effect the 
medicines would have on their lives and the other their view on the effects of not 
taking their medications precisely as directed. 
Psychological distress was measured by short forms of the Center for Epidemiological 
Studies Depression (CES-D) scale (sum of seven four-point items, alpha coefficient = 
0.85) (Mirowsky and Ross, 1992) and the Perceived Stress scale (sum of four five-
point items, alpha coefficient= 0.52) (Cohen, Karmarck & Mermelstein, 1983). 
Patients were also asked how satisfied they were with the support from friends and 
family members (four-point scale, 'very dissatisfied' to 'very satisfied') and to what 
extent friends and family members helped them remember to take their medication 
(four-point scale, 'not at all' to 'a lot') (Chesney et aI., 2000). 
Alcohol and drug use was probed using questions on whether they had an alcoholic 
beverage in the last 30 days and how many drinks they usually have altogether. From 
these two answers an estimate of the number of alcoholic drinks consumed during the 
past month was made. Questions on drug usage included whether cocaine, 
amphetamines, heroin, and in the original questionnaire methadone treatment, had 
ever or in the past six months been taken (Chesney et aI., 2000). 
Socio-demographic questions included age, gender, ethnicity, educational status, 










For the purpose of this study certain changes were made to the original 
questionnaires: 
1. The cover sheet information of the study was altered. 
2. Instructions: The use of check was replaced with tick. 
3. Q3. Description of oneself: this was changed since it had no relevance for 
South Africa. 
4. Q4. Description oflevel of schooling completed, This was changed by 
dividing it into two questions reading 'what is the highest standard or grade 
you have passed' and ascertaining the level of post school qualifications. 
5. Q6 was added to ascertain the person's home language. 
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6. Q7. This question was omitted. The only prominence health insurance gains 
in South Africa are when the medical aid actually pays for anti retroviral 
therapy. 
7. Q8. Questions of where the person stayed were omitted. 
8. Q8. Changed treatment or recovery program: South Africa would most likely 
not have this level of sophistication in terms of treatment. This question was 
omitted. 
9. Option 11: No pharmacies or chemist would stock ART. This question was 
omitted. 
10. Q 19: Changed to spirits. 
11. Q I9b: Alteration was necessary in terms of what South Africans drink. 
12. Q19c: Ounces of beer had to be translated into cans of beer. 
13. Q21: The top 10 drugs used in South Africa are different to the USA: (Medical 
Research Council, SA). 
In all other respects the schedule follows Chesney et aL (2000) and includes the 
following sections (see appendix 4): 
A. Demographics: 1. Sex, 2. Age, 3. Racial description, 4. Level of school 
education, 5. Post school qualifications, 6. Home language, 7. Marital 
or living status, 8. Employed or not, 9. Household income since this is 
what is used by demographers to establish SES (Socio economic 
status), 10. Any Psychiatric or medical conditions, 11. Visits to doctor 











B. Three questions about self-efficacy; belief in treatment and knowledge 
of the effects of missing doses. 
C. Two questions on social support, one dealing with overall social 
support and another dealing with whom, if anybody, reminds the 
patient to take medication. 
D. Fourteen questions on the possible reasons for skipping medications. 
E. Daily dosages and how many tablets have to be taken each time. 
F. Dosages missed within the last four days. 
G. Scheduling of drugs and whether these instructions are being followed. 
H. Special instructions that accompany drug taking and whether they are 
being followed. 
1. Missing doses on weekends. 
J. When last the patient missed taking a dose. 
K. Center for Epidemiological Studies Depression Scale (7-point version). 
L. The Perceived Stress Scale (lO-point version). 
M. Alcohol and Drug Usage. 
Psychological Distress: The Perceived Stress scale used in the original testing by 
AACTG was 4-point item scale. The alpha coefficient in the original study was 0.52 
(Cohen et aI., 1983). In this research the lO-point scale with an alpha coefficient of 
0.84 is used (Cohen et aI., 1983). Since these scales were standardized on American 
samples the alpha coefficients for both the Center for Epidemiological Studies 
Depression (CES-D) scale as well as the Perceived Stress scale were calculated on 
data from the present sample (see page 38) . 
. The alcohol and drug usage section: The profile of the drugs most commonly used in 
the Western Cape was received from a researcher at the Medical Research Council in 
Cape Town (personal Communication, May 20, 2002). 
3.4. Motivation for the use of self-report 
For the purpose of this study the motivation for the use of self-report of adherence 
needs to be considered. The next section thus considers adherence measurement and 











According to a number of researchers there is no "gold standard" by which adherence 
may be measured and it can be carried out in a number of ways (Chesney et a1., 2000; 
Williams, 2001). Various methods have included adherence scales completed by 
patients, clinician assessment, pill counting, pill use and prescription, micro-processor 
based monitoring of drug taking, laboratory data on viral load changes, and CD4 
lymphocyte counts (Friedland, 1999 in Tsasis, 2001). All of these means of assessing 
adherence have difficulties attached and no ideal method exists (Chesney et al., 2000; 
Tsasis 2001; Williams, 2001). 
Self-report has been said to overestimate adherence when patients are adherent (Liu et 
aI., 2001; Corelli, 1991 in Tsasis, 2001). However, when patients are missing doses 
they are likely to report this and it has been supported by detectable viral genetic 
material in the bloodstream (Hecht, 1998 in Chesney et al., 2000; Haubrich et aI., 
1999; Shelton, 1998 in Tsasis, 2001). Another study found that the self-report 
assessment of adherence is significantly associated with "plasma mv concentrations" 
(Bangsberg, 1999, Hecht, 1998 in Chesney et al., 2000). Indirect support for 
structured patient report was obtained from Bangsberg et al. (2001) who found that 
these reports were more likely to be accurate than physician assessment when 
correlated with pill count. The reason according to Haubrich et al. (1999, p 1105) may 
be that "patients may exaggerate their adherence to please their providers." It was 
speculated by Bangsberg et al. (2001) that patients might be more reluctant to disclose 
poor adherence to their health care providers than to other interviewers and thus using 
self-report questionnaires would be more reliable. Further substantiation for the use of 
self- report was gained from Gordillo et al. (1999) who found that using a supervised 
pill-count and self-report gave similar adherence figures. It has also been suggested 
by Gordillo et al. (1999) that it is only the patients themselves who can accurately 
report their actual behaviour. 
Kleeberger et al. (2001) states that self-reported data is a valid indicator of adherence 
and supports the validity of the questionnaire as a useful tool in studies. That self-
reported data was a valid tool to use in studies, was also supported by Tuldra et al. 
(2000). Kleeberger et al. (2001) also stated that over-reporting was less likely to occur 
in a non- clinical setting. Self-report can be improved by limiting the length of recall 











days. Bangsberg et al. (2001), however, recommended that if self-report was being 
used people on ART should not be asked to remember beyond the last three days. 
Chesney et aI. (2000) on the other hand, recommended that it be extended to four days 
so that it includes a weekend when people were less likely to follow a schedule. The 
focus on the most recent adherence was to maximize recall and minimize bias 
(Chesney et aI., 2000). 
Another method of assessment includes electronic monitoring which relies on a 
microchip in the bottle cap to record the cap being opened, but this may in effect 
underestimate adherence because patients tended to remove more than one dose at a 
time (Chesney et aI., 2000; Liu et aI., 2001). Electronic monitoring is an expensive 
way of monitoring adherence (Chesney et aI., 2000). Another factor that may come 
into play is that patients can either throw their tablets away or even sell them 
(Dunbar- Jacob, 1993 in Tsasis, 2001). It was also found that pill-count tends to 
overestimate adherence (Liu et aI., 2001). 
Liu et aI. (2001) suggested that at least for clinical trials, a CAS (Composite 
Adherence Score) was used that included MEMS (Medication Event Monitoring 
Scheme), a pill-count and interview. Another suggestion to check for adherence was 
to use the pill identification test (PIT). This test is used in conjunction with self-report 
and, besides supplying a back up for adherence measurement, it also improves the 
patient's knowledge of the treatment they are on (parienti et aI., 2000). 
3.5. Data handling and statistical analysis 
All data was entered onto an Excel spreadsheet. The entries were checked by having a 
person reading the answers from the questionnaires to another person who checked to 
see whether the entries were correctly entered. Any mistakes were corrected. The data 
was then transferred onto a Statistica spreadsheet as used at the University of Cape 
Town and the data analysed by using version 6.0 of this statistical package. 
Data analysis was carried out in two phases. In the first phase descriptive statistics 
were calculated for most of the elements of the questionnaire. Further analysis 
consisted of performing cross tabulations and a stepwise regression analysis. This 











it to a stepwise regression analysis with missed doses as the dependent variable or 
outcome variable. One of the dependent variables, substance use, had to be recoded 
into: 1 = using a lot of alcohol or using hard or recreational drugs and 2= a little or no 
alcohol and marijuana use. Recoding of the outcome variable, "missing doses" (J), 
occurred due to the skewness of the distribution. It was recoded into three variables 
namely, never skipped doses, skipped dose(s) within the last month and skipped dose 
or doses more than three months ago. This was achieved by: 
11 = JO (never miss medication) 
J2= 11 + J2 (missed more than 3 months ago + missed l~ 3 months ago) 
13= J3 + J4 + J5 (missed 24 weeks ago + 1-2 weeks ago + within past week). 
Two scales, namely the CES- D and the Psychological distress scale were used in the 
questionnaire and the internal reliability was calculated for each of these scales using 
Cronbach's alpha. This measurement ranges from 0 (no internal reliability) to 1 
(absolute internal reliability). In order to conduct the Cronbach alpha on the Perceived 
Stress Scale some items that were scored in a positive direction had to be recoded by 
using the formula: 4-score on (L4, L5, L7 and L8). Alpha scores for the two scales 
were 0.82 for the CES-D scale and 0.84 for the Perceived Stress scale. Because of the 
high alpha scores the scores in the scales were summed for each participant. Average 












Chapter 4: Results 
4.1. Introduction 
Questionnaire returns from the different sites varied with some sites returning as 
many as 100% and others only 20%. A summary of the different sections of the 
questionnaire is presented, together with cross tabulations, Chi-square analysis and a 
Stepwise regression analysis and is followed by an overall summary of the results. 
4.2. Summary of the sections 
i. Background information (Section A) 
Study participants consisted of29 males and 13 females, with a mean age of38 years 
(range= 27- 55). The description supplied by the participants was that 15 would 
describe themselves as white and 27 as black (included Black and Coloured people). 
The median level of education was Grade 12. More than half of the participants had 
some post-school qualification. Two thirds reported working for pay outside of the 
home. The median monthly income ranged from R2001- R5000. Twenty-four 
reported having a household income of less than R5000 and 17 reported having an 
income of more than R5000. Twenty reported English as a home language, 15 Xhosa 
and three Mrikaans. Twenty-four of the participants were single, 16 were either 
married or living with a significant other and two were either divorced, separated or 
widowed. 
ii. Self-efficacy, treatment efficacy and knowledge of the effects of missing 
medication (Section B) 
A vast majority (95%) believed that they could take their medication as prescribed. 
The belief in the efficacy of the drugs participants were given was high with 93% 
believing it would have a positive effect on their health. A lesser percentage (76%) 
believed that missing medication could make them resistant to HIV medication. 
iii. Social Support (Section C) 
In terms of social support 93% were satisfied with the support they received. Social 










with 45% receiving no to a little support whilst 50% receiving some to a lot of 
support. 
iv. Complexity of regimens (Section E) 
The vast majority (90%) of this sample is on bi-daily dosing. The rest are on once a 
day and three times a day. Complexity of the regimen could therefore not be used 
further as a variable because of the lack of variability in the sample. The average 
amount of tablets being taken for each day= 8 (std dev= 2.22). In the Chesney et al. 
study (2000) the participants were averaging between 10 and 25 pills per day. 
v. Missed HN medication (Section F, J and I) 
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Thirty eight percent of the sample (n= 16) never skips medications. The data collected 
indicates a high incidence of skipping doses with 26 (62%) of the participants 
skipping doses. Of these, 15 skipped doses more than one month ago and 11 had 
skipped doses within the past month. Although this figure does not indicate the 
frequency with which people are skipping doses it does, however, indicate that doses 
are being skipped and for the purposes of this study would be deemed non-adherent 
for the actual numbers skipping doses within the specified time frames: see 
histograms below. The 14% who skipped doses within two days prior to answering 
the questionnaire was similar to the finding of Chesney et aI., (2000). Only 15%, 
however had skipped doses the prior weekend whereas in the Chesney et al. (2000) 
study, twenty one percent had skipped doses. 
A large percentage of the participants had taken all their doses within the last four 
days. Recent non-adherence occurred: 14% had skipped doses during the prior two 
days. (Three (7%) had skipped doses on one day and three had skipped doses on two 
days). 15% had missed taking their doses during the prior weekend. 
vi. Reasons for missing HIV medications (Section D) 
Among participants who reported missing doses at some point in the past (N= 26), the 
most common reason was "feeling depressed and overwhelmed." Half reported this 
as one of the reasons for not taking medication. Other ranked common reasons 
include: a. simply forgetting, believing the drug was toxic/harmful and feeling good; 











in daily routine, felt sick, difficulty in following specified scheduling; e. avoidance of 
side effects, sleeping through dose and f running out of pills. (See histograms in 
appendix 6). 
When compared with the Kennedy (2000) study the ranking, as supplied by the South 
African sample, of the five top reasons why doses were skipped is very similar. On 
this ranking list the avoidance of side effects was low as with the Kennedy study 
(2000). Noticeable on this list was the number of people who believed the drugs were 
toxic/harmful and that feeling good meant skipping doses. A surprising result was 
how low down on the list "people noticing them taking medication" was. 
vii. Following schedules and special instructions attached to HIV medications 
(Section G and H) 
Eighty percent of the participants take their pills as prescribed, with approximately 
10% not following instructions as to the timing of the doses. 
62% of the participants have special instructions attached to taking their pills. Of 
these a half follow these instructions all the time, whilst another third follow the 
instructions most of the time to half of the time. The rest follow the instructions some 
of the time to never. 
viii. Alcohol and Drug usage (Section M) 
Nearly 60% of the participants either never use alcohol or use it only once a month. 
The rest are relatively evenly spread between two to three times a month to daily. 
Most of them do not have more than two drinks at a time, with a lesser amount having 
the maximum of four drinks. Only one participant used more than 12 drinks per day. 
In response to how many of the participants who drink, drink more than five drinks in 
a row (N= 24),42% responded never, 10% drank five drinks or more in a row once a 
month and the rest was spread evenly between two and three times a month, once or 
twice a week and three to four times a week. It appears that the use of alcohol in this 
sample is moderate. 
Participants reported very low recent use of recreational drugs (0- 10%). The drug of 











cocaine/crack (14%). Of the reported percentages approximately half reported recent 
use. In the Chesney study 46% had used cocaine/crack and 37 % had used 
amphetamines. 
4.3. Further analysis of data. 
Further exploration of the data occurred firstly by asking the question of whether 
there existed a difference between friends and families assisting the black and white 
patients to remember to take their mv medications (Question A3 recoded and C2). A 
cross-tabulation of race by social support in reminding patients to take medication 
was performed and submitted to a Pearson's Chi-square. 
Table 1: Cross-tabulation of recoded race by support to remember medication 
Not at all A little I Somewhat I A lot ! Total 
help_ : 
Black 4 (23%) 2 (12%) 0 11 (65%) 17 
White 12(52%) 1 (4%) 5 (22%) 5 (22%) 23 
All Grps 16 3 5 16 40 
A cross-tabulation of recoded Race by Social support for remembering to take mv 
medications was conducted. Pearson's Chi-square test revealed that there was a 
significant difference in the support offered in reminding patients to take their 
medication [Chi2 = 10.929 (Df= 3); p= 0.012]. A trend was that black people seemed 
to receive greater support than white people in remembering to take their mv 
medications. Note that with correlations all have to be treated with caution because 
the numbers within the different cells are small due to the small sample size and 
therefore only trends can be noted. 
Secondly what was investigated was whether there was a difference between black 
and white patients in terms of adherence (Question A3 recoded and J recoded). A 
cross tabulation was performed and submitted to Chi-square analysis. These tests 
revealed that there was no difference between black and white respondents on self-











A third question that was posed was which factors contribute to patients missing 
medications? This was investigated using stepwise regression. This analysis involved 
creating new variables namely, the outcome variable J (adherence), a single score for 
each individual on the CES-D scale and a single score for the Perceived stress scale 
and a recoded substance use (for further explanation, see methodology section). 
Seven variables namely, self efficacy, belief in treatment, knowledge of the effects of 
skipping doses, family helping to remember medication, sum of depression scale, sum 
of the perceived stress scale and the recoded substance used as independent variables 
and whether they had skipped doses or not as the dependent variable or outcome 
variable. 
Table 2: Stepwise regression analysis 
Regression Summary for Dependent Variable: IlDV 
R= .55927390 R2:: .31278729 Adjusted R2:: .27113803 
F(2,33)=7.5100 p<.00205 Std. Error of estimate: .68155 
S1. Err. S1. Err. 
BETA of BETA B ofB 
Intercpt 2.190231 .320350 
• B3 -.402584 .144625 -.318494 .1l4416 





Although only 27 % of the variance could be explained by this regression analysis it 
may mean that the variance was due to other factors not tapped. The variable most 
likely to act as a barrier to adherence in this sample was depression (Ksum) and the 
variable most likely to act as a facilitator to adherence was the knowledge and belief 
that if medications were not taken then the participant's body could become resistant 
to mv medications (B3). 
4.4. Summary of results 
There existed a strong belief among the participants that they could take their 
medication as prescribed. They also demonstrated a strong belief in the treatment they 
were taking. A lesser knowledge and beliefwas demonstrated about the effects of 











Most of the participants were satisfied with the social support they received. A strong 
trend emerged that blacks received more help with remembering to take their 
medications. 
Most of the participants were on bi-daily dosing with an average of eight tablets taken 
per day. A large percentage had taken all their medication within the last four days 
before completing the questionnaire. Most took their medication on time with only 
10% not following instructions. With regard to the special instructions attached to 
taking the medication, of the 62% with special instructions, one half followed the 
instructions and the rest followed the instructions most of the time to never. 
The most common reasons for participants missing doses were firstly: feeling 
depressed and overwhelmed; secondly, equal numbers stated that they simply forgot, 
believed that the drugs were toxic or harmful and that they were feeling good: thirdly, 
that they were away from home and fourthly, that they were busy. 
There was no significant difference between the races when it came to missing 
medications. 
Alcohol and drug usage in recent months was low among these participants. 
A facilitator of adherence among this sample was the knowledge and belief that if 
they did not take their medication their bodies would build up resistant strains ofthe 












Chapter 5: Discussion and Conclusions 
This chapter offers conclusions based on the results of the previous chapter. The 
major findings are restated and an attempt is made to place it within a South African 
context. Limitations of the research are discussed and suggestions for future research 
are made. 
Patients seem to have a good knowledge of the working of the medication and a belief 
in the warnings against missing medication. This seems to act as a facilitator to 
adherence. However, what has to be noted is that the sites used are sites where clinical 
trials have occurred and are occurring. These patients may be trial patients and may 
be aware that ifthey do not adhere, and become resistant to the medication, their 
chances of being put on to another regimen may be limited. Therefore, the assumption 
that increasing knowledge and belief would increase adherence has certain limitations 
in this context. Increasing and fostering beliefs in the negative effects of not adhering 
may in fact be counter-productive because this kind of message holds elements of 
threat and fear, namely, if you do not adhere and develop resistant strains within this 
context then no other treatment option may be available. The scarcity of the drugs in 
South Africa may therefore be a facilitator in that the participants reporting of 
adherent behaviour may be influenced by this fact. Health promotion models should, 
according to Ruiter, Abraham & Kok (2000), provide specific instructions and 
prompts, rather than providing information that places emphasis on the negative 
consequences of not performing the specific behaviour. 
A barrier to adherence was depression. This variable is listed in a number of studies as 
a factor why people do not adhere (Chesney et aI., 1996; Kleeberger et aI., 2001). It 
means that constant checking of the patient's mood is necessary and that, even if a 
patient does not reach a psychiatric definition of depression, counseling may be 
necessary. Increasing counseling with respect to depression and the lifting of this 












The sample demonstrated that they believed that they could adhere to medication 
regimens, believed in the medication and had a good knowledge of what missing 
medication would mean but cognisance needs to be taken of the discussion above. 
This finding means that at least for this sample it augurs well for future adherence. 
Having both a belief in self and a belief in treatment means that they are more likely 
to adhere despite side effects (Johnston Roberts, 2000). 
In terms of social support a vast majority was satisfied with the support they received. 
A trend was that blacks received more support than whites in remembering to take 
medications. A parallel finding from Cote d' Ivoire was that the families of the 
patients involved themselves in the treatment (Dargouge, 2002). It would appear as if 
this is a trend that is worth investigating further. 
The ranking of the five top reasons why doses were skipped in the South African 
sample is very similar to those supplied by patients in the Kennedy study (2000). 
These reasons in South Africa are: depression, forgetfulness, beliefs in toxicity and 
harmfulness of the drugs, feeling good and being away from home. There was an 
expectation that item D6, "you did not want others noticing you taking medication" 
could indicate a fear of being stigmatized. Patients did not rank this item highly 
among reasons for not adhering. When looking at this particular item, what has to be 
considered is that they were on twice daily dosing, and therefore if they stayed at 
home during these dosing times, exposure to others seeing them taking their 
medication became slight. An issue attached to this was: when they were away from 
home, were they "deliberately forgetting" to take their medication with them? This 
needs further investigation. On this ranking list the avoidance of side effects was low, 
as with the Kennedy study (2000). In South Africa it was interesting to note that not 
many of the participants had noted side effect profiles as the reason for not taking 
medication. This may also thus be attributable to the belief in self and the belief in 
treatment that help the patient to adhere despite side effects. In the northern 
hemisphere, however, Boyle (2000) stated that as more drugs had become available 
and AIDS had become a chronic medical condition, people were no longer wanting or 











In terms of adherence, 14% had skipped doses in the last four days. Although self-
report may overestimate overall adherence, in this study the missed doses and the 
reason(s) for missing them were important. A concern is that if patients missed as few 
as five doses in a 100, then they may be at risk for the development of resistant strains 
of the virus (Bamberger et aI., 2000b; Wainberg & Friedland, 1998). This does mean 
that health professionals caring for people on ART should be constantly vigilant. 
The effect that the complexity of dosing regimens could have on adherence could not 
be carried further by this study because most of the participants were on a twice-daily 
dosing regimen. Orrell et aL (2001) had, however, already stated that three-times daily 
dosing acted as a barrier in their study. This needs to be investigated further within the 
South African context. These sites employed doctors who are well trained, who have 
been in the HIV/AIDS field for years and who were following the latest 
• 
recommendations in terms of dosing. It appears therefore that if doctors were well 
trained and used some of the latest dosing recommendations, twice-daily dosing led to 
higher adherence rates than three-times daily dosing (Kemppainen et aI., 2001). 
A large percentage ofthe participants had special instructions attached to taking their 
medication. Of these almost three quarters followed these instructions more than half 
the time. The nature of the instructions or the reasons why people do not follow these 
instructions were not investigated within the context of this study. This needs further 
investigation and needs to be followed up at the sites. 
The patients in this sample appear to use alcohol moderately and only a small 
percentage are using recreational dugs. Because of the small sample size the impact of 
alcohol and drugs on adherence needs to be re-investigated. 
Methodological concerns within this study include sample size, language issues and 
questions relating to using statistical analysis on this sample size. The number of 
variables contained in this study needs a large sample size. A further limitation is that 
the sample was not random, which could lead to biases within the data. The 
questionnaires were only available in English and Afrikaans and no Afrikaans 
questionnaires were requested. Translating the questionnaire into Xhosa was not 











section D and filled in this section even if they had missed medications more than 
three months ago. A further limitation was that the length oftime the participants 
were on the medication was not asked. This does introduce possible bias into the 
sample since adherence studies have found that generally adherence is high in the first 
few months but declined over a year (Tuldra et aI., 2000). A limitation also of this 
study was that self-reported adherence was used. Self-report, although having its 
advantages also have disadvantages such as patients overestimating adherence. 
Therefore this study could have had a clinical perspective attached such as a viral load 
count. 
For a study such as this it would have been preferable to have a research assistant at 
the site to deal with any queries. Errors were possible because if the respondent had 
difficulties, they often had to ask the nurse In charge for help. Biases therefore are a 
distinct possibility in answering questions relating to adherence to medication. 
The sample size dictated the amount of statistics and the type of statistics that could 
be performed. This also leads to care being taken with making predictions to a wider 
population. No significant correlation was found between race and adherence. 
Although a significant correlation was found between race and social support, such as 
that people were helping subjects to remember to take their medication, the only 
conclusion that can be drawn from a sample of this size is that it indicates a trend that 
needs further investigation. 
The sample size dictated that, in order to do a stepwise regression, seven variables had 
to be chosen. These variables were checked against the weighting of the various 
factors in the literature. In the stepwise regression analysis two of the variables, 
notably KSum (CES-D) and LSum (perceived Stress Scale) were highly positively 
correlated. This introduced multi-co linearity into the regression analysis and a 
decision had to be made to use one or the other. KSum was used because of its higher 
zero order correlation (KSum corr.= 0.35 with dependent variable and LSum corr.= 
0.22 with dependent variable). 
Using a stepwise regression with small sample size has certain limitations. The 











have such small numbers, the model cannot be used for predictive purposes. Another 
difficulty was that the sample was not random. A possible way to test this model 
would have been to collect a new sample and to run the regression. At this point, 
because a new sample was not available, no cross validation is possible. Also within 
this regression model it has to be noted that for example, social support and 
depression may be interconnected but because depression is a stronger variable in this 
regression, social support is excluded from the regression. 
Despite these limitations, this study adds to the literature on adherence issues within a 
developing country. A facilitator to adherence was the belief and knowledge 
surrounding the consequences of not adhering to antiretroviral medication. Using 
patients on drug trials within a developing country adds dynamics to findings that 
needs further investigation. Additional research within this context is indicated in how 
much fearl threat is optimal for adherence. The exact nature of the factors that are 
contributing to the depression felt by mv positive people on ART in this sample 
needs to be investigated. A further investigation could be the prevalence of depressive 
symptoms in PL WHA on ART in South Africa. A significant trend within this sample 
was that black families were involved in assisting patients with medication adherence. 
This trend needs further investigation. Although stigmatization with regard to 
adherence to medication appeared not to be an issue among this sample, this may 
have been because of the regimen requirements. It has, however, been shown tliat 
stigma is a barrier to adherence in TB medication (Dick, 1998). It may therefore be 
possible that if people on ART had to take medication in public or the workplace, they 
may feel the effects of stigmatization. However, this needs to be investigated further. 
Further research is also needed to investigate what the difficulties are in following the 
specific instructions attached to taking ART as well as finding ways of improving the 
numbers of people following these specific instructions. 
The access to ART in the public health system is an increasing possibility. However, 
in order to utilize resources optimally, continuing research needs to be done in order 
to identify facilitators and barriers so that facilitators can be promoted and barriers 











Because research on adherence is limited in South Africa, pilot studies such as this are 
important. The scarcity of the relevant drugs in South Africa means that the numbers 
of participants available for study are limited and trials sites have to be used, as with 
this study. This does, however, complicate the analyses of the data gained within this 
context. This suggests that much more research is needed to develop adherence 
models that are appropriate to a developing country context, and that an important 
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Appendix 2: ACTG Baseline adherence questionnaire II 
Source: http://www.fstrf.org/qol/a<tultqJ.htm! 












ACTG BASELINE ADHERENCE QUESTIONNAIRE II 
Patient Number Date of Patient Visit 
mmm dd yy 
Protocol Number I 0 I 0 I 0 I 
Form Week I 0 I 0 I 0 I 
Institution Code I I I I I I 
Key Operator Code 
FOR OFFICE USE ONLY - TEAR OFF SHEET 
INSTRUCTIONS TO THE STUDY NURSE: 
I I 
The BASELINE ADHERENCE QUESTIONNAIRE II SHOULD BE GIVEN TO THE SUBJECT PRIOR 
TO THE CLINICAL EXAM. The subject must be able to read at the sixth-grade level at a minimum to 
complete the questionnaire without additional assistance. 
It is important to be familiar with the content and format of the questionnaire before giving it to study 
participants. At the first visit, please begin by telling the participant: 
• The purpose of this form is to learn about potential influences of treatment adherence. 
• Please answer all questions honestly: you will not be "judged" based on your responses. 
• If you do not wish to answer a question, please draw a line through it. 
• When completed, the form will be quickly reviewed to make sure you didn't mistakenly skip 
questions (without crossing them out); your specific responses to questions will not be reviewed. 
• Please feel free to ask if you need any of the questions explained to you. 
You should then briefly go over the format of the questions and how to complete them. 
The questionnaire is very brief and should take no more than 10 minutes to complete. Before giving 
the subject the questionnaire, please fill out the header(s) and DETACH THIS PAGE. 
Each question is in the same general format and contains several items. Note that the subject is 
always asked to make a ",/" next to the appropriate category. 
Collect the completed questionnaire before the clinical exam. Before going on, review the 
questionnaire for omissions. If the participant missed any of the questions, point this out and 
encourage him/her to complete the omissions. 
For data keying, if the subject did not answer a question, enter "-1." Do not leave any fields blank. 
PLEASE COMPLETE THE FOLLOWING ITEMS AFTER SUBJECT COMPLETES THE 
QUESTIONNAIRE OR AFTER YOU ASCERTAIN THAT THIS IS NOT POSSIBLE: 
1. How was the questionnaire completed? ........... 1-Self administered by the study participant D 
2-Face-to-face interview that you conducted 
3-Both self-administered and interview 
4-Not completed 
9-0ther, specify 
If Other, specify [30]: _____________________ _ 
a. If you answered "4-Not completed," please indicate the reason why: 
1-Subject refused 
2-Subject missed clinic visit 
3-There was not enough time 
9-0ther reason, specify 













Protocol Number 1 01 010 1 1 1 Institution Code ..... 1 ----1..1----,,--,,,---,--....1---' 
Form Week Key Operator Code 
The answers you give on this form will be used to plan ways to help other people who must take pills 
on a difficult schedule. Please do the best you can to answer all the questions. If you do not wish to 
answer a question, please draw a line through it. If you do not know how to answer a question, ask 
your study nurse to help. Thank you for helping in this important study. 
INSTRUCTIONS: Please answer the following questions by placing a "V'" in the appropriate box. 
A. How sure are you that: 
(Check one) 
Please check one box for each question. 
Not At All Somewhat Very Extremely 
Sure Sure Sure Sure 
1. You will be able to take all or most of the 0 0 0 0 
study medication as directed? 0 1 2 3 
2. The medication will have a positive effect 0 0 0 0 
on your health? 0 1 2 3 
3. If you do not take this study medication 
exactlyas instructed, the HIV in your 0 0 0 body will become resistant to HIV 0 1 2 3 
medications? 
B. The following questions ask about your social support. 
(Check one) 
Please check one box for each question. Very Somewhat Somewhat Very 
Dissatisfied Dissatisfied Satisfied Satisfied 
1. In general, how satisfied are you with 
D 0 D the overall support you get from your 
friends and family members? 0 1 2 3 
Not At A Not 
All Little Somewhat A lot Aeelicable 
2. To what extent do your friends or family 
D D D D members help you remember to take 












ACTG BASELINE ADHERENCE QUESTIONNAIRE II ~e 3 of 6 
Patient Number rn I I I I I D Date of Patient Visit ~ 
'--m-'-m---Lm---J dd yy 
C. People may miss taking their medications for various reasons. Here is a list of possible reasons 
why you may have missed taking any medications within the past month. 
If you have NOT taken any medications within the past month, please check this box 
and skip to Section D: ........................................................................................ 0 
In the past month. how often have you missed taking your medications because you: 
(Check one) 
Please check one box for each question. Some-
Never Rarel~ Times Often 
1. Were away from home? 0 0 0 0 
0 1 2 3 
2. Were busy with other things? 0 0 0 0 
0 1 2 3 
3. Simply forgot? 0 0 0 0 
0 1 2 3 
4. Had too many pills to take? D 0 0 
0 1 2 
5. Wanted to avoid side effects? D 0 0 
0 2 3 
6. Did not want others to notice you taking D 0 0 0 
medication? 0 1 2 3 
7. Had a change in daily routine? D 0 
0 2 
8. Felt like the drug was toxic/harmful? D 0 0 
0 1 2 3 
9. Fell asleep/slept through dose time? D 0 0 0 
0 1 2 3 
10. Felt sick or ill? D 0 0 
0 1 2 
11. Felt depressed/overwhelmed? D 0 0 0 
0 1 2 3 
12. Had problem taking pillS at specified 
D 0 0 0 times (with meals. on empty stomach, 
etc.)? 0 1 2 3 
13. Ran out of pills? 0 0 0 
0 1 2 
14. Felt good? D 
0 
D. When was the last time you missed taking any of your medications? 
(Check one box) 
Within the past week 5 
1-2 weeks ago 4 
2-4 weeks ago 3 0 
1-3 months ago 20 
More than 3 months ago 1 0 
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ACTG BASELINE ADHERENCE QUESTIONNAIRE II 
Patient Number IT] I I I I I D Date of Patient Visit I I I ~e40f6 iLUIT] 
dd yy 
E. In the past week how often did you: 
Please check one box for each question. 
1. Feel like you couldn't shake off the blues 
even with help from your family or friends? 
2. Have trouble keeping your mind on what 
you were doing? 
3. Feel that everything you did was an 
effort? 
4. Have trouble sleeping? 
5. Feel lonely? 
6. Feel sad? 
7. Feel like you just couldn't "get going"? 
F. In the past month, how often have you: 
Please check one box for each question. 
1 . Been upset because of something that 
happened unexpectedly? 
2. Felt unable to control the important things 
in your life? 
3. Felt nervous and "stressed"? 
4. Felt confident in your ability to handle 
your personal problems? 
5. Felt that things were going your way? 
6. Found that you could not cope with all 
the things that you had to do? 
7. Been able to control irritations in your life? 
8. Felt that you were on top of things? 
9. Been angered because of things that 
happened that were outside of your 
control? 
1 O.Felt problems were piling up so high that 
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ACTG BASELINE ADHERENCE QUESTIONNAIRE II Page 5 of 6 
Patient Number OJ I 1110 Date of Patient Visit I IOJ OJ 
mmm dd yy 
G. People have various health habits. The following questions ask about your alcohol and drug 
use, past and current. 
1. How often have you had a drink containing alcohol - a glass of beer, wine, 
a mixed drink, or any kind of alcoholic beverage - in the last 30 days? 
Nearly 
Daily Every Day 
D D 




If Never, skip ahead to question 4. 
Once or 
Twice A Week 
D 
3 












2. On days when you drank any alcoholic beverages, in the last 30 days, how many drinks did 
you usually have altogether? By a drink, we mean a can or glass of beer, a 4-ounce glass of 
wine, a 1 Yz ounce shot of liquor, or a mixed drink with 1 Yz ounces of liquor. 
1 or 2 Drinks 
Per Day 
3 or4 Drinks 
Per Day 
5 or 6 Drinks 
Per Day 
7 or 8 Drinks 
Per Day 
9 -11 Drinks 
Per Day 
(Check one) 
12 or More 
Drinks Per Day 
D D D D D D 
o 1 2 3 4 5 
3. During the past 30 days, how often have you had 5 or more drinks of alcohol in 
a row, that is, within a couple of hours (e.g., 2-4 hours)? (Check one) 
Nearly 3 or4 Times Once or 2 or3 Times Once A 
Daily EveryDay A Week Twice A Week A Month Month Never 
D D D D D D D 
6 5 4 3 2 1 0 
4. Please check "Ves" or "No" for each question: 
a. D Ves D No Have you ever used marijuana? 
1 2 
If you used this drug, have you used it within the past 6 months? 
DVes D No 
1 2 
b. D Ves D No Have you ever used cocaine (powder, crack, freebase)? 
1 2 
If you used this drug, have you used it within the past 6 months? 
DVes D No 
1 2 
c. D Ves D No Have you ever used heroin? 
1 2 
If you used this drug, have you used it within the past 6 months? 
DVes D No 
1 2 
d. D Ves D No Have you ever used amphetamines (speed)? 
1 2 
If you used this drug, have you used it within the past 6 months? 
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Patient Number rn I I I Date of Patient Visit I I IT] IT] 
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5. Are you currently in methadone treatment? ................................. D Ves D No 
If Yes, skip to Question H 1 2 
If No, have you ever been in methadone treatment? ................. D Ves D No 
1 2 
H. These last questions ask about your background. 
1. What is the highest level of education you have completed? 
11 th grade or less 
(Check one box) 
oD 
High school graduate or GED 
2 years of college/AA degreeITechnical school training 
College graduate (BA or BS) 
Masters degree 
Doctorate/medical degree/law degree 





(Check "Yes" or "No" for each question.) 
a. Sex with a man who was HIV+ ................................................ . 
b. Sex with a woman who was HIV+ ............................................ . 
C. Shared needles with a person who was HIV+ ........................... .. 
d. Blood transfusion or other medical procedure ......................... .. 
e. Don't know .......................................................................... . 








If Other, please specify: ______________ _ 
3. Do you work for pay outside the home? DVes ONo 
1 2 
4. Do you have any children? 0 Yes 0 No 
1 2 
If Yes, how many live with you? ................................................ CD 
Thank you very much for completing these questions. 
The information that you provided will help with 














Appendix 3: ACTG Adherence follow-up questionnaire 
Source: http://www.fstrf.org/golJadult qLhtml 












ACTG ADHERENCE FOLLOW-UP QUESTIONNAIRE 
Patient Number Date of Patient Visit 
mmm 
Institution Code Protocol Number I 0 I 0 I 0 I 
Form Week I I I I Key Operator Code 
FOR OFFICE USE ONLY - TEAR OFF SHEET 
INSTRUCTIONS TO THE STUDY PERSONNEL: 
I I 
The ACTG ADHERENCE FOLLOW-UP QUESTIONNAIRE SHOULD BE GIVEN TO THE SUBJECT 
PRIOR TO THE CLINICAL EXAM. The subject must be able to read at the sixth-grade level at a 
minimum to complete the questionnaire without additional assistance. 
It is important to be familiar with the content and format of the questionnaire before giving it to study 
participants. At the first visit, please begin by telling the participant: 
• The purpose of this form is to learn about potential influences of treatment adherence. 
• Please answer all questions honestly; you will not be "judgedn based on your responses. 
• If you do not wish to answer a question, please draw a line through it. 
• When completed, the form will be quickly reviewed to make sure you didn't mistakenly skip 
questions (without crossing them out); your specific responses to questions will not be reviewed. 
• Please feel free to ask if you need any of the questions explained to you. 
For question "A," review with the subject what treatment they are receiving and complete the 
worksheet together. You should then briefly go over the format of the questions and how to 
complete them. 
The questionnaire is very brief and should take no more than 5 minutes to complete. Before giving 
the subject the questionnaire, please fill out the header(s) and DETACH THIS PAGE. 
Each question is in the same general format and contains several items. Note that the subject is 
always asked to make a "../" next to the appropriate category. Drug names and abbreviations of the 
most common anti-HIV drugs and of any other study drugs have been included on the worksheet for 
reference and use. 
Collect the completed questionnaire before the clinical exam. Before going on, review the 
questionnaire for omissions. If the participant missed any of the questions, point this out and 
encourage him/her to complete the omissions. 
For data keying, if the subject did not answer a question, enter "-1." Do not leave any fields blank. 
PLEASE COMPLETE THE FOLLOWING ITEMS AFTER SUBJECT COMPLETES THE 
QUESTIONNAIRE OR AFTER YOU ASCERTAIN THAT THIS IS NOT POSSIBLE: 
1. How was the questionnaire completed? .... ..... 1-Self administered by the study participant 
2-Face-to-face interview that you conducted 
3-Both self-administered and interview 
4-Not completed 
9-0ther, specify 
If Other, specify [30]: ______________________ _ 
a. If you answered "4-Not completed," please indicate the reason why: D 
1-Subject refused 
2-Subject missed clinic visit 
3-There was not enough time 
9-0ther reason, specify 












ACTG ADHERENCE FOLLOW-UP QUESTIONNAIRE 
Patient Number Date of Patient Visit 
Protocol Number I 01 01 01 
Form Week I 1 I I 
THIS PAGE IS TO BE COMPLETED BY THE SUBJECT AND STUDY PERSONNEL TOGETHER. 
INSTRUCTIONS: Complete this worksheet with the subject. Drug names and abbreviations of the 
possible study medications have been included for your reference and use. Use the abbreviations 
indicated (i.e., "APV" for Amprenavir). 
A. You are currently taking the following study drugs at the frequency and doses listed: 
Study Regimen 
Study Drug 



















# Pills Each Time 
(Pills Each Dose) 
GW433908 
Indinavir/lDV/Crixivan 
Interleu kin-2/1 L-2 
Lamivudine/3TC/Epivir 
# Times Per Day 
(Doses Per Day) 
Lopinavir/Ritonavir (LPV/RlV)/Kaletra ABT-378/r 
Loviride/Lotrene 
Nelfinavir/NFV Ni racept 
Nevirapine/NVPNiramune 
Ritonavir/RlV INorvir 
Saquinavir soft gel/FlV/Fortovase 
Saquinavir (HGC)/SQV II nvirase/R031-8959 
T -20/pentafuside 
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Patient Number CD I I I I I D Date of Patient Visit I I I LLJ CD 
mmm dd yy 
The answers you give on this form will be used to plan ways to help other people who must take 
pills on a difficult schedule. Please do the best you can to answer all the questions. If you do 
not wish to answer a question, please draw a line through it. If you do not know how to answer a 
question, ask your study nurse to help. Thank you for helping in this important study. 
SlIB .. IECT ONLY continue here. 
The next section of the questionnaire asks about your study medications that you took over 
the last four days. Drug codes and abbreviations of the possible study medications have been 
included for your reference and use on page 2. 
~ Most people with HIV have many pills to take at different times during the day. 
Many people find it hard to always remember their pills: 
• Some people get busy and forget to carry their pills with them. 
• Some people find it hard to take their pills according to all the instructions, 
such as "with meals" or "on an empty stomach," "every 8 hours," "with plenty of fluids." 
• Some people decide to skip pills to avoid side effects or to just not be taking 
pills that day. 
We need to understand how people with HIV are really doing with their pills. Please tell us 
what you are actually doing. Don't worry about telling us that you don't take all your pills. 
We need to know what is really happening, not what you think we "want to hear." 
1. The next section of the questionnaire asks about the study medications that you may have 
missed taking over the last four days. Please complete the table below, using one line for 
each study medication you are taking, and using the abbreviations on the previous page. If 
you did not miss any doses, write a zero (0) in the box. Note that the table asks about 
DOSES, not PILLS. 
IF YOU TOOK ONLY A PORTION OF A DOSE ON ONE OR MORE OF THESE DAYS, 
PLEASE REPORT THE DOSE{S) AS BEING MISSED. 
HOW MANY DOSES DID YOU MISS ... 
Step 1 Step 2 Step 3 Step 4 Step 5 
Day before 
Abbreviations/Names Yesterday yesterday 3 days ago 4 days ago 
of your study drugs (2 days ago) 
D doses D doses D doses D doses 
D doses D doses D doses D doses 
D doses D doses D doses D doses 
D doses D doses D doses D doses 
D doses D doses D doses D doses 
D doses D doses D doses D doses 
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Patient Number rn I I I I I D Date of Patient Visit I I ILU [I] 
mmm dd YV 
The following questions pertain to the study regimen on page 2. 
If you took only a portion of a dose on one or more of these days, please report the dose(s) 
as being missed. 
B. During the past 4 days, on how many days have you missed taking all your doses? 
(Check one box) 
None 00 
One day 10 
Two days 2 D 
Three days 3 D 
Four days 40 
C. Most study medications need to be taken on a schedule, such as "2 times a day" or "3 times a 





















D. Do any of your study medications have special instructions, such as "take with food" or "on 





If Yes, how often did you follow those special instructions over the last four days? 
Some Of About Half Most Of All Of 
The Time Of The Time The Time The Time Never 
o DO D 
.0 2 3 4 
E. Some people find that they forget to take their pills on the weekend days. Did you miss any of 





F. When was the last time you missed any of your medications? 
(Check one box) 
Within the past week 5 D 
1-2 weeks ago 4 D 
2-4 weeks ago 3 0 
1-3 months ago 20 
More than 3 months ago 1 
Never skip medications 0 D 
If you Never miss your study medications, please STOP. 
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Patient Number 
G. People may miss taking their study medications for various reasons. Here is a list of possible 
reasons why you may miss taking your medications. How often have you 
missed taking your study medications because you: (Check one) 
Please check one box for each question. 
1. Were away from home? 
2. Were busy with other things? 
3. Simply forgot? 
4. Had too many pills to take? 
5. Wanted to avoid side effects? 
6. Did not want others to notice you taking 
medication? 
7. Had a change in daily routine? 
8. Felt like. the drug was toxic/harmful? 
9. Fell asleep/slept through dose time? 
10. Felt sick or ill? 
11. Felt depressed/overwhelmed? 
12. Had problem taking pills at specified 
times (with meals, on empty stomach, etc.)? 
13. Ran out of pills? 


























































Thank you very much for completing these questions. 
The information that you provided will help with 





















































Many people taking HIV medications sometimes find it difficult to remember 
what pills to take, when to take them, how to take them (with food - without food) 
and for other reasons. 
By assisting us with this questionnaire you will be helping us to research these difficulties 
and help find possible solutions to overcome them. We need you to be open 
and honest about how you feel in having to take these medications daily, and possibly for life. 
It is voluntary to answer these questions and the answers you give us will not be shared 
with your relatives or friends. All answers will be confidential. 
Do not write your name. 










Instructions: Please read each question carefully. Tick ''./ " the answer of your choice or answer in writing. 
There is no right or wrong answer. 
A: Background Information: 
1. VVhat is your sex? 
2. How old are you? 
3. How would you describe yourself! 
If "Other", please specifY _________ _ 
4. VVhat is the highest standard or grade you have passed? 










If''YES'' - please specifY ______________ _ 





If "Other", please specifY _________ _ 
7. Are you? 
Single 
Married or Living with significant other 










8. Do you work for pay outside the home? 





RSOO 1- R8000 
R8001- RI0000 
More than RIOOOO 




1. Psychiatric problem (e.g. for your nerves) 1 
2. High blood pressure 1 
3. Sugar 1 
4. Arthritis/rheumatism 1 
5. TuberculosisffB 1 
6. Cancer 1 
7. Other (Specify __ ~ _______ ---.J 1 
11. Have you visited your doctor in relation to treatment for HIV/ AIDS in the past six months 
Yes 
If YES - How many times did you visit your doctor? 
No 
1 - 2 times 
3 -4 times 

















Instructions: Please answer the following questions by placing an II J "in the appropriate box. 
B: The questions below are about taking medications for mY/AIDs. 
Please tick one box for each question: 
Not At All 
Sure 
1. How sure are you that you will be able to 0 
take all or most of the HIV medication as 
directed? 
2. How sure are you that the HIV medication 0 
will have a positive effect on your health? 
3. How sure are you that if you do not take 0 
the HIV medication exactly as instructed, 
the HIV in your body will become resistant 
to HIV medications? 
C: The following questions ask about your social support. 
Please tick one box for each question: 
1. In general, how satisfied are you with the 
overall support you get from your friends 
and family members? 
2. To what extent do your friends 
or family members help you 





















































D: People may miss taking their HIV medication for various reasons. Here is a list of possible reasons 
why you may have missed taking any medication within the past month. 
In the past month, how often have you missed taking your mv medication/pills because: 
Please tick one box for each question: (Tick one) 
Never Rarely I Sometimes I Often 
1. You were away from home? 0 1 2 3 
2. You were busy with other things? 0 1 2 3 
3. You simply forgot? 0 1 2 3 
4. You had too many pillsltablets to take? 0 1 2 3 
5. You wanted to avoid side effects? 0 1 2 3 
6. You did not want others to notice you 0 1 2 3 
taking medication? 
7. You had a change in daily routine? 0 1 2 3 
8. You felt like the drug was toxiclharm:ful? 0 1 2 3 
9. You fell asleep/slept through the dose time? 0 1 2 3 
10. You felt sick or ill? 0 1 2 3 
1 LYon felt depressed/overwhelmed? 0 1 I 2 3 
12. You had problems taking the pills/tablets 0 1 2 3 
at specified times (with meals, on empty 
stomach, etc)? 
13. You ran out of pills/tablets? 0 1 2 3 










Instructions: Please answer the following questions by placing an ".j "in the appropriate box. 
E: The next section asks how many and how often you take medication for mY/AIDs. 
1. I have to take my pills: 
Once a day 
(tick one box) 
Twice a day 
Three times a day 
Four times a day 
2. How many pills do you take for each dose? 
Please write in the appropriate boxlboxes the amount of pills. 
Once a day 
Twice a day 
Three times a day 
Four times a day I 
F: The next section asks about the mv medication that you may have missed taking over the 
past four days. 
If you only took a portion of a dose on one or more of these days, please report the dose(s) as 
being missed. 






(tick one box) 
1 
o 
G: Most mv medications need to be taken on a schedule, such as "twice a day" or "three times a day" or 
"every 8 hours" • 
1. How closely did you follow your instructions to take your HIV pills? (tick one box) 
Never 
Some of the time 
About half of the time 
Most of the time 










H: Do any of your mv medications have special instructions, such as "take with food" or If on an empty 
stomach" or "with plenty Ouids"? 
(tick one box) 
Yes 
No 
If YES - How often did you follow those special instructions over the past four days? 
EE 
(tick one box) 
Never 0 
Some of the time 
About half of the time 
Most of the time 
All of the time 
I: Some people find that they forget to take their mv pills on the weekend days. Did you miss any of your 
medications last weekend (last Saturday or Sunday)? 
(tick one box) 
J: When was the last time you missed taking any of your HIV medications? 
Yes 
No 
Within the past week 
1 - 2 weeks ago 
2 - 4 weeks ago 
1 - 3 months ago 
More than three months ago 











K: The next section asks how you have been feeling. 
Please tick one box for each question: (Tick one) 
Neverl Mostly or 
Rarely Sometimes Often Always 
1. In the past week, how often did you feel 0 I 2 3 
like you couldn't shake off the blues even 
with the help from your fiunily or friends? 
2. In the past week, how often did you have 0 1 2 3 
trouble keeping your mind on what you 
were doing? 
3. In the past week, how often did you feel 0 1 2 3 
that everything you did was an effort? 
4. In the past week, how often did you have 0 I 2 3 
trouble sleeping? 
5. In the past week, how often did you feel 0 I 2 3 
lonely 
6. In the past week, how often did you feel 0 I 2 3 
sad? 
7. In the past week, how often did you feel 0 I 2 3 
like you just couldn't "get going"? 
L. In the past month, how often have you: 
Please tick one box for each question: (Tick one) 
Almost Some- Fairly Very 
Never Never times Often Often 
I. Been upset because of some- 0 I 2 3 I 4 
thing that happened 
unexpectedly? 
2. Felt unable to control the 0 I 2 3 4 
important things in your life? 










L. (Continued) In the past month, how often have you: 
Please tick one box for each question: 
4. Felt confident in your ability to 
handle your personal problems? 
5. Felt that things were going 
your way? 
6. Fouod that you could not cope 
with all the things that you had 
to do? 
7. Been able to control irritations 
in your life? 
8. Felt that you were on top of 
thing ? s. 
9. Been angered because of 
things that happened that were 
outside of your control? 
10. Felt that problems were piling 




















Some- Fairly Very 
times Often Often 
2 3 4 
2 3 4 
2 3 4 
2 3 4 
2 3 4 
2 3 4 
2 3 4 
M: People have various health habits. The following questions ask about your alcohol and drug use, 
past and current. 
1. How often have you had a drink: containing alcohol - a glass of beer , wine, a mixed drink, 
or any kind of alcoholic beverage - in the past 30 days? 
Daily 
Nearly every day 
3 or 4 times a week 
Once or twice a week 
2 or 3 times a month 
Once a month 
Never 
If NEVER - Skip to question 4. 











2. On days when you drank alcoholic beverages, in the past 30 days, how many drinks did you 
usually have altogether? By a drink, we mean a can or glass of beer, a glass of wine, a tot 
of spiritsfliquor, or a mixed drink with a tot of spiritsfliquor. 
1 or 2 drinks per day 
3 or 4 drinks per day 
5 or 6 drinks per day 
7 or 8 drinks per day 
9 - 11 drinks per day 
12 or more drinks per day 
3. During the past 30 days, how often have you had 5 or more drinks of alcohol in a row, that 
is, within a couple of hours (e.g., 2-4 hours)? 
(tick one box) 
4. Please tick ''YES'' or ''NO" for each question: 
a: Have you ever used marijuana/ dagga? 
Daily 
Nearly every day 
3 or 4 times a week 
Once or twice a week 
2 or 3 times a month 




If YES - Have you used it within the past six months? 




















c: Have you ever used heroin? Yes 
No 
If YES - Have you used it within the past six months? 





If YES - Have you used it within the past six months? 





If YES - Have you used it within the past six months? 





If YES - Have you used it within the past six months? 
Yes 
No 
Thanks for taking the time to answer these questions. We appreciate your 










Baie mense wat MIV medikasie moet neem, vind dit soms moeilik om te onthon watter 
pille om te neem, wanneer om die pille te neem, hoe om die pille te neem (met maaltye, 
nie met maaltye) en om 'n verskeidendheid ander redes. 
Met jon samewerking denr die vroolys te beantwoord, sal jy ons help om hierdie 
redes na te vors en om met moontlike oplossings vorendag te kom. Wees asseblief 
oop en eerlik oor jon gevoelens omdat jy hierdie medikasie daagliks en moontlik 
vir altyd moet neem. 
Die beantwoording van die vraelys is vrywillig. Jon antwoorde is vertroulik 
en sal nie met jon vriende of familie gedeel word nie. 
Moenie jon naam op die vraelys neerskryf nie. 










Instruksies: Lees asseblief elke vraag aandagtig deur. Merk " I" die antwoord van jou keuse, of skryf die 
antwoord neer. Daar is geen regte ofverkeerde antwoorde nie. 
A: Agtergrond: 
1. Wat is jou geslag? 
2. Hoe oud is jy? 








Indien "Ander", spesifiseer asseblief __________ _ 
4. Wat is die hoogste standerd (graad) wat jy behaal het? 
5. Het jy enige na-skoolse kwalifikasies? 
Ja 
Nee 
Indien "Jail, spesifiseer asseblief: _____________ _ 





Indien "Ander", spesmseer asseblief __________ _ 
7.Isjy? 
Enkellopend 
Getroud of woon saam met besondere ander 










8. Verdienjy 'n inkornste buite die huis? 





R500 1- R8000 
R800 1- RIOOOO 
Meer as RIOOOO 
Ja 
Nee 
10. Neem jy op die huidige oomblik voorgeskrewe medikasie vir enige van die volgende? 
Ja 
1. Psigiatriese probleme (bv. Vir jon sennwees) 1 
2. Hoe bloeddruk 1 
3. Suiker 1 
4. Arthritis/rheumatiek 1 
5. TuberkuloseITB 1 
6. Kanker 1 
7. Ander (spesifiseer asseblief. _______ -') 1 
11. Het jy jon dokter besoek gedurende die afgelope 6 maande vir MIV IVIGS behandeling? 
Ja 
Nee 
Indien "Ja", hoeveel keer het jy jon dokter besoek? 
1 - 2 keer 
3 -4keer 





















Instruksies: Antwoord asseblief die volgende vrae deur die nodige blokkie te merk " 1". 
B: Die volgende afdeling verwys na die neem van MIVMGS medikasie: 
Kies asseblief een blokkie vir elke vraag (kies een) 
Glad nie Baie Geheel en 
sekeroie Seker seker al seker 
1. Hoe seker is jy dat jy die meeste of al 0 1 2 3 
jou medisyne sal kan neem? 
2. Hoe seker is jy dat the MIVIVIGS 0 1 2 3 
medikasie In positiewe effek op jou 
gesondheid sal he? 
3. Hoe seker is jy, dat as jy nie jou MIV 0 1 2 3 
medikasie sou neem soos aangewys nie, die 
MIV in jou liggaam hestand sal raak: teen 
die MIV medisyne. 
C: Die voIgende vrae verwys na jou ondersteuoings netwerk: 
Kies asseblief een blokkie vir elke vraag (kies een) 
Baie Baie 
Ontevrede Ootevrede Tevrede Tevrede 
1. In die algemeen, hoe tevrede is jy 0 1 2 3 
oor die algehele ondersteuning van jOl.l 
vriende of familielede? 
Glad Baie I Nut Nie Min n Bietjie Baie 
2. Tot watter mate help jou 0 1 2 3 4 
vriende of familie lede jou om 











D: Mense mag om verskeie redes vergeet om hulle MIV medikasie te neem. Hier is 'n lys van 
redes waarom jy mag vergeet om jou medikasie te neem. 
Gedurende die afgelope maand, hoe gereeld hetjy vergeet omjou medikasie te neem a.g.v. die volgende 
redes? Kies asseblief een blokkie vir elke vraag (kies een) 
Nooit Min Soms I Gereeld 
1. Jy was me by die hois me? 0 1 2 3 
2. Jy was besig met ander dinge? 0 1 2 3 
3. Jy het eenvoudig vergeet? 0 1 2 3 
4. Jy het te veel pille/tablette gehad om te 0 1 2 3 
neem? 
5. Jy WOll me die newe- effukte beleefhet me? 0 1 2 3 
6. Jy WOll me he dat ander moet sien dat jy 0 1 2 3 
medikasie neem me? 
7. Daar was 'n verandering in jon daaglikse 0 1 2 I 3 
roetiene? 
8. Jy het gevoel dat die medikase giftig was 0 1 2 3 
vir jOll sisteem? 
9. Jy het geslaap tydens dosistyd? 0 1 2 3 
10. Jy het siek gevoel? 0 1 I 2 3 
11. Jy was depresief/ neerslagtig? 0 1 I 2 3 
12. Jy het dit moeilik geviod om die 0 1 2 3 
medikasie tydens gespesifiseerde tye te 
neem (met maaltye, op 'n lee maag, ens)? 
13. Jy het geen pille oor gehad mel Jou pille 0 1 2 3 
wasop? 










Instruksies: Antwoord asseblief die volgende vrae deur die nodige blokkie te merk It I". 
E: Die volgende afdeling verwys na die hoeveelheid en gereeldheid waarmee jy jou MIV medikasie 
moetneem. 
1. Jy moet jou pille neem: 
2. Hoeveel pille moetjy neem vir elke dosis? 
(Kies een) 
Een maa1 per dag 
Twee maal per dag 
Drie maa1 per dag 
Vier maa1 per dag 
Skryf asseblief die hoeveelheid pille wat jy moet neem in elke blokkie. 
Een maa1 per dag 
Twee maa1 per dag 
Drie maa1 per dag 
Vier maa1 per dag I 
F: Die volgende afdeling verwys na die hoeveelheid kere jy vergeet bet om jou MIV medikasie 
te neem gedurende die afgelope 4 dae. 
Indien jy slegs In gedeelte van In dosis geneem het op een of meer van die dae, meld asseblief dat 
die dosis me geneem is me. 







G: Die meeste MIV medikasies moet volgens 'n skedule geneem word, by. een maal per dag, 
twee maal per dag of elke 8 ure? 
1. Gedurende die afgelope 4 dae, hoe streng het jy die instruksies gevolg? (Kies een) 
Nooit 
Soms 
Helfte van die tyd 











H: Het enige van jou MIV medikasie spesifieke instruksies soos byvoorbeeld, "neem met 








Helfte van die tyd 
Meeste van die tyd 
AI dietyd 
I: Sommige mense vergeet om huDe MIV medikasie te neem oor naweke. Het jy vergeet om jou 
medikasie te neem gedurende die afgelope naweek? 
Ja 
Nee 
J: Wanneer was die laaste keer wat jy vegeet het om jon MIV medikasie te neem? 
(kies een) 
(kies een) 
Gedurende die afgelope week 
1-2 weke gelede 
24 weke gelede 
1-3 maande gelede 
Meer as 3 maande gelede 










K: Die volgende afdeling verwys na jou emosionele toestand I hoe jy voel. 
Kies asseblief een blokkie vir eJke vraag. (kies een) 
Nooit IM:-.;anl Min Soms Gereeld 
1. Gedurende die afgelope week, hoeveel 0 1 2 3 
keer het jy afgemat gevoel en kon jy nie die 
gevoel afskud nie, selfs met die help van jou 
vriende offamilie? 
2. Gedurende die afgelope week, hoeveel 0 1 2 3 
keer het jy gevoel asof jy nie kon konsentreer 
op waarmee jy besig was nie? 
3. Gedurende die afgelope week, hoeveel 0 1 2 3 
keer het jy gevoel clat aIles wat jy doen 
baie moeite verg? 
4. Gedurende die afgelope week, hoeveel 0 1 2 3 
keer het jy dit moeilik gevind om te slaap? 
5. Gedurende die afgelope week, hoeveel 0 1 2 3 
keer het jy aIleen gevoel? 
6. Gedurende die afgelope week, hoeveel 0 1 2 3 
keer het jy bartseer gevoel? 
7. Gedurende die afgelope week, hoeveel 0 1 2 3 
keer het jy gevoel dat jy nie aan die gang 
konkomnie? 
L: Gedurende die afgelope maand, hoe gereeld; 
Kies asseblief een blokkie vir eJke vraag. (kies een) 
I 
Amper I Amper Nooit Nooit Soms Gereeld Altyd 
1. Was jy onge1ukkig omclat iets 0 1 2 3 4 
onverwags gebeur het? 
2. Het jy gevoel asof dit 0 1 2 3 4 
ontmoontlik was om beheer te 











L: (Vervolg) Gedurende die afgelope maand, hoe gereeld; 
Kies asseblief een blokkie vir elke vraag. (kies een) 
I Amper I Amper Nooit Nooit Soms Gereeld Altyd 
3. Was jy senuweeagtig of 0 1 2 3 4 
gestres? 
4. Het jy selfversekerd gevool in 0 1 2 3 4 
jou vermoe om jou persoonlike 
probleme nit te sorteer? 
5. Het jy gevool asof dinge in jou 0 1 2 3 4 
guns was? 
6. Het jy gevoel dat jy nie alles 0 1 2 3 4 
wat jy moos doen, kon 
behartig nie? 
7. Kon jy die irritasies in jou lewe 0 1 2 3 4 
hanteer? 
8. Hetjy gevool asofjy alles 0 1 2 3 4 
onder beheer gehad het? 
9. Was jy kwaad omdat dinge 0 1 2 3 4 
wat gebeur het, buite jou beheer 
was? 
10. Het jy gevool dat dinge te 0 1 2 I 3 4 










M: Gesondheidsgedrag verskil tussen mense. Die volgende vrae verwys na jou alkobol en 
dwelmgebruik buidiglik en in die verlede. 
1. Gedurende die afgelope 30 dae, hoe gereeld bet jy 'n drankie grdrink ('n glas bier, 'n glas 
wyn, 'n gemengde drankie of eruge iets alkoholies)? 
Daagliks 
Amper elke dag 
1 - 2 maal per week 
3 - 4 maal per week 
2 - 3 maal per maand 
Een maal per maand 
Nooit 
Indien ''Nooit'' - gaan assebliefna vraag 4. 
(kies een) 
2. Gedurende die afgelope 30 dae, hoeveel drankies het jy gedrink per dag? 'n Drankie verwys na 
'n blikkie of'n glas bier, 'n glas wyn, of'n gemengde drankie (vb brandewyu en coke) 
1 - 2 drankies per dag 
3 - 4 drankies per dag 
5 - 6 drankies per dag 
7 - 8 drankies per dag 
9 - 11 draukies per dag 
(kies een) 
12 of meer drankies per dag 
3. Gedurende die afgelope 30 dae, hoeveel keer het jy vyf of meer drankies namekaar gehad? 
(bv. binne 2 - 4 ure) 
Daagliks 
Amper elke dag 
1 - 2 maal per week 
3 - 4 maal per week 
2 - 3 maal per maand 












4. Merk asseblief "Jail of "Nee" vir elk van die volgende vrae. 
a. Het jy ooit vantevore daggalmarajiuana gebruik? Ja 
Nee 
Indien "Ja", hetjy dit gedurende die afgelope 6 maande gebruik? 





Indien "Ja", hetjy dit gedurende die afgelope 6 maande gebruik? 





Indien "Ja", hetjy dit gedurende die afgelope 6 maande gebruik? 





















e. Hetjy ooit vantevore kokaiene (coke/cracklfreebase) gebruik.? 
Ja 
Nee 
Indien "Ja", het jy dit gedurende die afgelope 6 maande gebruik? 





Indien "Ja", hetjy ditgedurende die afgelope 6 maande gebruik? 
Dankie vir jou samewerking. 
Ja 
Nee 











Appendix 6: Histograms of reasons for missed doses 
In the figures below the numbers of participants recording various reasons for missing 
doses are shown. Legend for all the histograms: 0= never; 1 = rarely; 2= sometimes; 
3= often. In order to rank these responses 1,2 and 3 were added to give a sum of the 
number of participants who had responded affirmatively. Ranking 1 = most used 
reason etc. 
Figure 1: Responses to section D question 11 (You felt depressed/overwhelmed?). 
HlsWgral11 (~STA 95v"42c) 
3 
Ranking 1 
Figure 2: Responses to section D question 3 (You simply forgot?) 

























Figure 3: Responses to section D question 8 (You felt like the drug was 
toxic/harmful?) 
Histogram (da1a8aUQ2.STA 95..,.42c) 
33 
Ranking 2 
Figure 4: Responses to section D question 14 (You felt good?). 
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Figure 5: Responses to section D question 1 \'lou were away from home?) 
Histogram (dalaBaug2STA 95v"42c) 
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Figure 6: Responses to section D question 2 \'lou were busy with other things?) 
H.~ram (dI!laBauli2,$TA 95v'42c) . .... , . 
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Figure 7: Responses to section D question 4 (you had too many pills/tablets to take?) 
Histogram (dala8aug2.STA 9511"42c) 
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Histogram (data8aug2.STA 95v"42c) 
4 
07 















Figure 11: Responses to section D question 11 (You had problems taking the 









Histogram (dataBaug2.STA 9Sv"42c) 
4 
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Figure 12: Responses to section D question 5 (You wanted to avoid side effects?) 
. . . . . 
" Histogram (daf8Baug2Sr A 9Sv" 42cJ 
" 3Q::r" ~-,--,-...;...c.;-,-~ __ ...;...c.;~ ___ ~ __ --'-____ ---',,", 





















Figure 13: Responses to section D question 9 (You fell asleep/slept through the dose 
time?) 
Histogram (data8aug2.STA 95v*42c) 
Ranking 6 
Figure 14: Responses to section D question 13 (You ran out of pills/tablets?) 
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